Human rpL3 regulates DNA damage reponse by modulating p21(waf1/cip1) levels in a p53-independent manner by Esposito, Davide
  
 
UNIVERSITA’ DI NAPOLI FEDERICO II 
 
DOTTORATO DI RICERCA 
BIOCHIMICA E BIOLOGIA CELLULARE E 
MOLECOLARE 
XXVI CICLO 
 
 
 
 
Human rpL3 regulates DNA damage response 
by modulating p21(waf1/cip1) levels  
in a p53-independent manner 
 
 
 
Davide Esposito 
 
 
 
 
 
 
 
 
 
 
Academic Year 2013/2014
 
UNIVERSITA’ DI NAPOLI FEDERICO II 
 
DOTTORATO DI RICERCA 
BIOCHIMICA E BIOLOGIA CELLULARE E 
MOLECOLARE 
XXVI CICLO 
 
 
 
 
Human rpL3 regulates DNA damage response 
by modulating p21(waf1/cip1) levels  
in a p53-independent manner 
 
 
 
Davide Esposito 
 
 
 
 
 
 
 
 
Tutor      Coordinator 
Prof. Giulia Russo      Prof. Paolo Arcari 
 
 
Co-tutor 
Prof. Caterina Missero 
 
 
 
 
 
 
 
 
!"!
!
Riassunto 
 
Il gene CDKN1A codifica per p21waf1/cip1 (p21), inibitore delle 
chinasi ciclina-dipendenti, che è capace di arrestare il ciclo cellulare in fase 
G1 in situazioni di stress tra cui un danno indotto al DNA. É inoltre 
coinvolto anche in altre funzioni cellulari come ad esempio la regolazione 
dell’apoptosi. Il gene CDKN1A è principalmente regolato a livello 
trascrizionale dalla proteina soppressore del tumore p53, tuttavia è riportata 
in letteratura una modulazione indipendente da suddetta proteina. Molti dati 
in letteratura indicano che svariate proteine ribosomali, oltre ad intervenire 
nella sintesi proteica esercitano dei ruoli extraribosomali. 
 L’attività da me svolta durante il dottorato è stata indirizzata alla 
comprensione del ruolo della proteina rpL3 nell’espressione p53-
indipendente di p21 ed il significato biologico di tale regolazione. 
A tale scopo ho valutato l’attività trascrizionale del gene CDKN1A in 
condizione di iperespressione di rpL3 attraverso un saggio di luciferasi ed 
ho valutato tramite RT-PCR e Western Blotting i livelli di mRNA e di 
proteina p21. Ho condotto, inoltre, esperimenti di immunoprecipitazione 
della cromatina e di EMSA per valutare l’abilità di rpL3 di interagire con il 
promotore di p21 e la natura di tale legame. Allo scopo di identificare i 
partner proteici di rpL3 che mediano questo legame, ho analizzato il ruolo 
svolto dalle proteine NPM ed Sp1, entrambe coinvolte nella regolazione 
trascrizionale di p21, attraverso esperimenti di immunoprecipitazione della 
cromatina e saggi di luciferasi, ed, utilizzando mutanti del promotore di p21, 
identificato la regione di tale promotore responsabile del legame di rpL3.  
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Inoltre, ho eseguito esperimenti di analisi del ciclo cellulare e della 
vitalità cellulare in seguito a danno al DNA indotto dal trattamento con 
farmaci chemioterapici (5-fluorouracile e oxaliplatino) in condizioni di 
iperespressione e di silenziamento di rpL3. Successivamente ho indagato la 
regolazione dell’espressione di p21 mediata da rpL3 in condizioni di danno 
al DNA ed analizzato il ruolo svolto da rpL3 nell’attivazione dei 
meccanismi di riparo del DNA in seguito al trattamento con i suddetti 
farmaci. Questi esperimenti hanno dimostrato che il trattamento con farmaci 
chemioterapici provoca un aumento della quota proteica di rpL3 non legata 
ai ribosomi. Questa frazione libera di rpL3, regolando l’espressione di p21, 
è responsabile del blocco della proliferazione cellulare in risposta ad un 
danno di lieve entità, o dell’induzione dell’apoptosi per inibizione dei 
meccanismi di riparo per ricombinazione omologa e non omologa, qualora il 
danno sia maggiore e non riparabile. Questi esperimenti hanno inoltre 
dimostrato che quest’azione sembra essere in parte indipendente da p21. 
Complessivamente gli esperimenti condotti durante il mio progetto di 
dottorato hanno dimostrato che rpL3 esercita una funzione extraribosomale 
in condizioni di stress cellulare, regolando l’espressione di p21 attraverso un 
meccanismo indipendente da p53. In particolare, rpL3 sembra fungere da 
mediatore di stress svolgendo una funzione antitumorale attraverso il blocco 
della proliferazione cellulare o l’induzione dell’apoptosi in dipendenza 
dall’entità dello stress subito dalla cellula. 
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Summary 
!
The CDKN1A gene encodes for the protein p21waf/cip1 (p21), 
inhibitor of chinase cyclin-dependent, that is able to induce G1 cell cycle 
arrest under stressing conditions such as DNA damages and is also involved 
in other cell functions as regulation of apoptosis.  
CDKN1A is mainly regulated at transcriptional level by the tumor 
suppressor protein p53, although a p53-independent regulation of p21 
expression has been reported. Several ribosomal proteins exerts 
extraribosomal functions besides their main role in the translation process.  
The aim of this study is to understand the role of the ribosomal protein 
rpL3 in p53-independent regulation of p21 expression and the biological 
significance of this regulation.  
To this aim, I investigated the transcriptional activity of CDKN1A 
upon rpL3 overexpression by a reporter luciferase assay and analyzed p21 
mRNA and protein levels through RT-PCR and Western Blotting. To 
evaluate the ability of rpL3 to interact with p21 promoter I performed ChIP 
and EMSA experiments. Then, to identify protein factors that mediate the 
interaction between rpL3 and p21 promoter, I analyzed the role of NPM and 
Sp1 proteins, both involved in p21 trancriptional regulation, through ChIP 
experiments and reporter luciferase assays. Furthermore, using p21 promoter 
mutants, I was able to identify the promoter region responsible for this 
interaction. 
Next, cell cycle and cell viability analysis were performed after DNA 
damage induction mediated by chemotherapeutic drugs (5-fluorouracil, 
oxaliplatin) while altering  rpL3 levels. 
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Then, I investigated the rpL3-mediated regulation of p21 expression 
upon DNA damage and analyzed the role played by rpL3 in the regulation 
of DNA repair mechanisms. These data showed that DNA damage induces 
accumulation of free-ribosome rpL3. This amount of rpL3, regulating p21 
expression, is responsible for cell cycle arrest in response to a mild DNA 
damage, and apoptosis when the damage in higher and not reparable. In 
addition, these experiments demonstrated that the role of rpL3 is partially 
independent of p21. 
These experiments demonstrated that rpL3 exerts an extraribosomal 
function upon ribosomal stress, regulating p21 expression through a 
mechanism independent of p53. In particular, rpL3 seems to act as tumor 
suppressor inhibiting cell proliferation or triggering apoptosis in dependent 
of the nature of the stress. 
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1. Introduction 
 
1.1 Extraribosomal functions of ribosomal proteins 
Ribosomal proteins (RPs) are abundant RNA-binding proteins found 
in every cell. In addition to their role in the ribosome, it has been reported 
that some RPs also have other functions. For example, the bacteriophage Q! 
encodes a polypeptide that binds to three E. Coli host proteins, the 
translation factors EFTu, EFTs and the rpS1, to serve as the RNA replicase 
responsible for replication of its genome (Warner and McIntosh, 2009). 
Stoichiometry of ribosomal components is essential for ribosome 
synthesis, requiring equimolar production of ribosomal RNA (rRNA) and 
some 70 to 80 RPs. In E. coli, this is carried out largely by the RPs, which 
can function extraribosomally as translational repressors of RP synthesis. As 
an example, the S10 operon encodes 11 different RPs, one of which is rpL4 
that can inhibit translation of the entire operon by binding to the 5’UTR of 
the S10 operon mRNA (Lempiainen and Shore, 2009). 
Such autoregulation of RP production is less common in eukaryotic 
cells, but there are several documented cases of RPs regulating their own 
synthesis. In our laboratory it has been demonstrated that rpL3 is able to 
regulate its production. In addition to canonical mRNA isoform normally 
translated into protein, the rpL3 gene produces an alternative mRNA 
isoform, containing a PTC (premature termination codon) degraded by 
NMD (Nonsense mediated-mRNA decay). Overexpression of rpL3 causes 
an increase in the level of alternative unproductive mRNA isoform, which 
results in a decrease of rpL3 production (Cuccurese et al., 2005). This is 
clearly an extraribosomal function, but not in an extraribosomal system. Of 
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note, the negative feedback loop triggered by the accumulation of rpL3, 
represents a strategy that finely regulates the amount of ribosomal protein to 
an appropriate level, that could be relevant especially to other 
extraribosomal functions of rpL3. Furthermore, recent data suggest a role 
for rpL3 in tumors and drug resistance. In several malignancies, telomerase 
activity is upregulated during cancer progression; microarray analyses of 
gene expression profile in different esophageal carcinoma cell lines showed 
that rpL3 level positively correlated with telomerase activity (Kondoh et al., 
2001). Moreover, proteomic analysis indicated that rpL3 might be involved 
in the induction of 5-fluorouracil (5-FU) resistance in human colon cancer 
cells (Tanaka et al., 2008).  
 
1.2 Ribosomal stress 
Ribosome biogenesis is the most demanding energetic and metabolic 
expenditure of the cell. The entire process is estimated to use more than 
60% of cellular resources and therefore it is carefully monitored for quality 
control. Increasing evidence indicates that surveillance of ribosome 
assembly plays an important role in the cellular self-evaluation, in which 
defects in ribosome synthesis can lead to cell cycle arrest or apoptosis 
through extraribosomal functions of RPs (Castro et al., 2008).  
Alterations in the expression of RPs and protein factors involved in the 
ribosome biogenesis seem to correlate with tumorigenesis since many of 
these proteins are overexpressed in solid tumors and leukemia cells. On the 
other hand, some data suggest that several RPs might function as tumor 
suppressors, as described in zebrafish (Amsterdam et al., 2004). A picture of 
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the complex choreography through which RPs act as sentinels of defects in 
ribosome assembly is gradually developing. 
Recently, an increasing number of RPs have been proposed as p53 
activators, leading to cell cycle arrest and apoptosis. In response to nucleolar 
stress, the ribosomal components rpL11, rpL5, rpL23, and rpS7 are released 
from the nucleolus into the nucleoplasm where they associate with Mdm2, 
inhibiting its E3 ubiquitin ligase activity toward p53 and thus promoting p53 
stabilization and activation (Deisenroth and Zhang, 2010). In addition, 
rpL26, which is ubiquitinated by MDM2, binds to the 5!-UTR of p53 
mRNA and increases its translation in response to DNA damage. Lastly, 
rpS3 interacts directly with p53 and protects it from Mdm2-mediated 
ubiquitination induced by oxidative stress (Ofir-Rosenfeld et al., 2008). It 
has been shown that rpL23 regulates p21 gene promoter transactivation 
mediated by nucleophosmin (NPM), a nucleolar protein involved into 
ribosome maturation, and Myc-interacting zinc finger protein 1 (Miz1) by 
sequestering NPM into the nucleolus (Wanzel et al., 2008). Thus, both 
nucleolar and ribosome biogenesis-related proteins are very important 
regulators of the nucleolar stress signaling cascade that leads to p53 
activation. 
Very recently, some light has been shed on the presence of p53-
independent pathways regulating the relationship between ribosome 
biogenesis and cell proliferation in mammalian cells. For example, it has 
been demonstrated that ribosomal stress causes a decrease in the levels of 
the serine/threonine kinase PIM1. Consequently, the inhibitor of the cell 
cycle  p27Kip1, target of PIM1, increases thus blocking cell proliferation 
(Iadevaia et al., 2010) (Fig. 1.1). 
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Figure 1.1: Ribosomal stress. Schematic representation of the p53-dependent and 
independent cell cycle arrest after ribosomal stress. 
 
1.3 p21waf1/cip1 
p21 (also known as p21waf1/cip1) is a key regulator of cell cycle 
progression involved in a vast array of complex interactions and networks 
within the cell. Various regulatory mechanisms contribute to finely 
coordinate multiple biological functions of p21 altering its levels. They 
include transcriptional regulation, epigenetic silencing, mRNA stability, 
ubiquitin-dependent and ubiquitin-independent degradation of the protein 
(Jung et al.).   
p21 can function as a tumor suppressor by mediating G1 growth arrest 
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by inhibiting the kinase activity of cyclin-dependent kinases (CDKs) CDK1 
and CDK2. However, in certain cellular contexts p21 may also act as an 
oncogene since it may display tumorigenic and antiapoptotic activities 
(Abbas and Dutta, 2009). For example, p21 protects against apoptosis 
induced by sodium butyrate in U937 cells (Rosato et al., 2004), and by 
prostaglandin A2 in human colorectal carcinoma (Gorospe et al., 1996). On 
the other hand, there is evidence that p21 may also be proapoptotic through 
either p53-dependent or p53-independent mechanisms under certain cellular 
stresses (Tsao et al., 1999; Yang et al., 2003). However, this effect has been 
observed mainly associated with the ectopic overexpression of p21. 
Furthermore, p21 gene overexpression in p53-null human laryngeal 
squamous carcinoma cells can assume a dual role in the regulation of 
apoptosis depending on drug treatment; in fact p21 overexpression enhances 
apoptosis in cisplatin-treated cells whereas it attenuates apoptotic signals in 
methotrexate-treated cells (Kraljevic Pavelic et al., 2008).  
Besides p53, a variety of transcription factors can modulate p21 
(Macleod et al., 1995). The majority of p21 gene regulatory proteins interact 
with the proximal region of p21 promoter. This region includes six GC-rich 
binding sites that are recognized by Sp1, Sp3 and Kruppel-like trascription 
factors (Koutsodontis et al., 2002; Wu and Lingrel, 2004). Substantial 
evidence supports the essential role of Sp1 in the upregulation of p21 gene 
by several protein factors such as c-Myc (Gartel et al., 2001) or drugs such 
as 5-FU and Sulforaphane (Chew et al., 2012; Koutsodontis and Kardassis, 
2004). Recently, it has been suggested that p21 could also play a role in 
several pathways involved in the DNA damage response. However, the 
relationship of p21 activity with these pathways is not yet clear and the role 
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of p21 remains controversial (Abbas and Dutta, 2009). 
 
 1.5 Aim of the study 
It is now well documented that ribosomal stress, defined as an 
alteration of ribosome synthesis owing to a variety of causes including DNA 
damage, causes the binding of several ribosomal proteins to Mdm2. This 
event relieves Mdm2 inhibitory activity toward p53, leading to p53 
activation that results in a p53-dependent inhibition of cell proliferation 
(Castro et al., 2008). 
A number of reports suggest that perturbations of ribosome biogenesis, 
can activate specific checkpoints and block cell proliferation also through 
p53-independent mechanisms, involving ribosome biogenesis-related 
proteins and regulators of cell proliferation such as p21 (Zhang and Lu, 
2009). 
We have studied post-transcriptional regulatory strategies of 
mammalian RPs, and we have demonstrated that rpL3 autoregulates its own 
expression through the association of alternative splicing and nonsense-
mediated mRNA decay (AS-NMD) in order to fine tune the levels of protein 
that exert extraribosomal functions (Cuccurese et al., 2005). 
The aim of my thesis project is to investigate the molecular 
mechanism by which rpL3 might modulate the intracellular levels of p21 
independently of p53 and to understand how this regulation may affect 
chemotherapy response. 
"
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2. Materials and Methods 
 
2.1 Cell cultures, transfections and drug treatment 
Human cell lines Calu-6 (Cuccurese et al., 2005) and HCT-116p53-/- 
were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) with 
glutamax (Invitrogen, Carlsbad, California) supplemented with 10% fetal 
bovine serum (FBS), 0.1 mM non-essential amino acids (Euroclone, West 
York, UK), 2mM L-glutamine and penicillin-streptomycin 50 U/ml. 
p21!Calu-6 cell line, derived from Calu-6 cell line and stably silenced 
for p21, was grown in DMEM supplemented with 10% fetal bovine serum 
(FBS), 0.1 mM non-essential amino acids (Euroclone), 2mM L-glutamine, 
penicillin-streptomycin 50 U/ml and 0,5 µg/ml puromycin (Sigma-Aldrich). 
siRNA transfections were performed in Calu-6 and HCT-116p53-/- cells 
(2,5 x 106 cells, 6 mm-well plate) at a concentration of 150 nM using 
Oligofectamine Reagent (Invitrogen) according to the manufacturer’s 
instructions.  
Plasmids were transfected in Calu-6, HCT-116p53-/- and p21!Calu-6 
cells (2,5 x 106 cells, 60 mm-well plate) by using Lipofectamine 2000 
(Invitrogen) according to the manufacturer’s instruction. 
After DNA transfections, RNA and proteins were extracted by using 
the Trizol procedure (Invitrogen) for RT–PCR analysis and western blot, 
respectively.  
Transfection efficiency was assessed by cotransfecting a GFP-
expressing vector and normalizing RNA levels against GFP mRNA levels 
(data not shown). 
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Calu-6 cells (2,5 x 106 cells, 60 mm-well plate) were treated with 200 
nM Mithramycin A (Sigma-Aldrich) for 16 hours before transfections or 
chromatin immunoprecipitation. Drug treatments were performed after 
siRNA or DNA transfection by adding 10 µM or 100 µM of 5-Fluorouracil 
or OXHliplatin (Sigma-Aldrich, St. Louis, Missouri) to all cell lines. 
 
2.2 Plasmids  
The cDNA of NPM was obtained by RT–PCR from Calu-6 cells using 
the primers 5!-ATGGAAGATTCGATGGAC-3! (forward) and 5!-
TTAAAGAGACTTCCTCCA-3! (reverse), and cloned into a version of the 
eukaryotic expression vector pcDNA3.1/His C (Invitrogen) containing the 
FLAG epitope. The construct was verified by DNA sequencing. 
The cDNA of Sp1 was obtained by RT–PCR from Calu-6 cells using 
the primers 5!- ATGGATGAAATGACAGCT-3! (forward) and 5!-
TCAGAAGCCATTGCCACT-3! (reverse), and cloned into a version of the 
eukaryotic expression vector pcDNA3.1/HisMyc A (Invitrogen) containing 
the His epitope. The construct was verified by DNA sequencing. 
The plasmids encoding HA-rpL3, HA-NPM, rpL7a-His and were 
already available (Russo et al., 2011). The plasmids pWWP, pWP124, 
pWP101 and pWPdel-Sma I were kindly provided by Dr. Yoshihiro Sowa 
(Huang et al., 2000). 
The I-SceI expression vector pCAGGS-ISceI was a gift from Prof. E. 
Avvedimento. 
 
2.3 RNA interference 
The siRNAs targeting NPM and rpL3 were purchased from Santa Cruz 
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Biotechnology (Santa Cruz Biotechnology, Santa Cruz, CA, USA, sc-29771, 
sc-76400). 
To stably silence p21, Calu-6 cells were seeded the day before 
transfection in a 60 mm plate and 24 hours later they were transfected with 2 
µg of a p21 short hairpin RNA (shRNA) expressing pSM2c vector 
contained in the Expression Arrest™ human shRNA library (Open 
Biosystems, Huntsville, AL, USA). Transfected cells were selected with 1 
µg/ml of puromycin (Sigma-Aldrich) for 7 days and then the p21 depletion 
was evaluated by western blotting.  
The sense strand of the p21 shRNA sequence is: 5'- 
TGCTGTTGACAGTGAGCGACCAGCCTCTGGCATTAGAATTTAGTG
AAGCCACAGATGTAAATTCTAATGCCAGAGGCTGGGTGCCTACT
GCCTCGGA-3'.  
A short hairpin non-silencing construct was used as control.  
 
2.4 PCR 
For Reverse Transcriptase-PCR analysis, 1 µg of total RNA was 
reverse-transcribed into cDNA with the random primer hexamer technique 
using 200 U of Superscript II RNase H- Reverse Transcriptase (Invitrogen). 
The reaction was carried out at 42°C for 50 min and was terminated by 
heating to 75°C for 15 min. Ten of the 40 µl of reaction mix were PCR-
amplified in a final volume of 50 µl, using 5 µM of each specific primer, 
10 mM dNTPs and 0.5 U of Taq DNA polymerase (Invitrogen). Typically, 
25–30 cycles of amplification were performed. The primers were: cDNA 
p21 5’-CGCGGATCCATGTCAGAACCGGCTGGG-3’ (forward) and 5’- 
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CCGGAATTCATTAGGGCTTCCTCTTGGA-3’ (reverse); and "-actin 5!-
GGCACCACCTTCTACA-3! (forward) and 5!-CAGGAGGACAATGAT-3! 
(reverse). 
In separate experiments, we ascertained that the cycle number was 
within the linear range of amplifications. PCR products were visualized on 
1% agarose gel containing the fluorescent Vista Green dye (Amersham 
Pharmacia Biotech). The labeling intensity of the PCR product, which is 
linear to the amount of DNA, was quantified using the PhosphorImager 
(Bio-Rad, Haercules, California). 
Real time PCR was used to analyze DNA in ChIP experiments as 
described in the sub-section “Chromatin immunoprecipitation”. 
 
2.5 Western blotting 
For western blotting assay, protein samples (30 µg) were resolved by 
12% SDS-gel electrophoresis and transferred into nitrocellulose filters. The 
membranes were blocked in PBS, 0,2% Tween and 5% dry milk for 2h, and 
then challenged with anti-rpL3, anti-rpL7a (Primm, Milan, Italy), anti-
rpS19, anti-FLAG (Sigma-Aldrich, St. Louis, USA; F3165), anti-Sp1 
(Millipore, Billerica, USA; 07-645), anti-p21, anti-NPM, anti-HA, anti-His, 
anti-PARP and anti-"-tubulin (Santa Cruz Biotechnology, Santa Cruz, 
California; sc-397, sc-47725, sc-57592, sc-803, sc-7150, sc-8035). The 
proteins were visualized with enhanced chemiluminescence detection 
reagent according to the manufacturer’s instructions (Pierce, Rockford, 
Illinois). Loading in the gel lanes was controlled by detection of "-tubulin 
protein. 
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2.6 Chromatin immunoprecipitation 
Chromatin immunoprecipitation (ChIP) assay was performed starting 
from 1 x 106 Calu-6 cells. DNA and proteins were cross-linked by the 
addition of 1% formaldehyde for 10 min at room temperature, and cross-
linking was stopped by the addition of 125 mM glycine for 5 min at room 
temperature. Cells were then lysated in a RIPA buffer. Chromatin was 
fragmented by sonication to an average size of 500–1000 bp in sonication 
buffer and pre-cleaned with protein A-agarose. Ten microliters of each 
supernatant was removed as input, and the rest of the supernatant was 
immunoprecipitated with anti-rpL3, anti-NPM, anti-Sp1 antibodies, or 
normal mouse IgG overnight at 4°C. After immunoprecipitation, 30 µl of 
protein A-agarose was added and incubated for 1 h at 4°C to capture the 
immune complexes. The agarose beads were washed, 30 microliters of 
DNA-proteins immunocomplexes were resolved by 12% SDS-gel 
electrophoresis and transferred into nitrocellulose filters analyzed by 
western blotting. The chromatin was extracted from the remaining aliquots 
of DNA-proteins immunocomplexes, the protein–DNA crosslink was 
reversed, and the proteins were digested with proteinase K. DNA was then 
purified and analyzed by real-time PCR analysis with the primers, p21 
promoter (-194/+88) 5’-ACCGGCTGGCCTGCTGGAACT-3’ (forward) 
and reverse 5’- TCTGCCGCCGCTCTCTCACCT-3’ (reverse); p21 3’-UTR 
(+3455/+3771) 5’-ATGTTAGGCAAGTTACTTAACTTA-3’ (forward) and 
5’-CTCTTGGTAACTTCACACCAAGTT-3’ (reverse) using SYBR 
GreenEr qPCR SuperMix Universal (Invitrogen) following the 
manufacturer's instructions.  
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2.7 Dual Luciferase Assay 
Luciferase assays were performed with the Dual-Glo Luciferase assay 
system (Promega, Milan, Italy) following manufacturer’s instructions. 
Samples were read with Turner Luminometer and expressed as relative 
luciferase, i.e. RT/RC, where RT and RC are (Firefly luciferase)/(Renilla 
luciferase). 
 
2.8 Cell cycle analysis 
Cells were collected in PBS 1X and fixed in 70% ethanol. Before 
analysis, fixed cells were washed twice, centrifuged and resuspended in 1 ml 
of PBS containing 10 µg/ml of RNase and 50 µg/ml of propidium iodide 
(Sigma-Aldrich). Subsequently fluorescence of propidium iodide was 
detected in a linear scale using a CyAn ADP Flow Cytometer 
(DAKOCytomation, Ely, UK) and analysed using Summit Software. 
 
2.9 BrdU incorporation 
For BrdU (5'-Bromo-2'-deoxyuridine) incorporation, Calu-6 or HCT-
116p53-/- cells were labeled for 40 minutes with 20 µM BrdU (Sigma-
Aldrich), harvested and fixed in 70% ethanol. Subsequently, cells were 
incubated with 20 µl of anti-BrdU-FITC antibody (BD Biosciences, Italy) 
for 45 min in dark at room temperature. Cells were then washed twice with 
PBS 1x + Tween 0,1%, centrifuged and resuspended in 1 ml of PBS 
containing 10 µg/ml of RNase and 5 µg/ml of propidium iodide (Sigma-
Aldrich). Samples were analyzed by a CyAn ADP Flow Cytometer 
Materials and Methods!
 
%("
(DAKOCytomation) and quantified using Summit Software. 
 
2.10 Mitochondrial membrane potential measurement 
To quantify changes in mitochondrial membrane potential, Calu-6 or 
HCT-116p53-/- cells were labeled with 0.1 µM of the mitochondrial 
membrane potential–sensitive fluorescent dye, tetramethylrhodamine ethyl 
ester (TMRE) (Invitrogen), for 30 min at 37°C, analyzed by a CyAn ADP 
Flow Cytometer (DAKOCytomation) and quantified using Summit 
Software. 
 
2.11 Ribosome isolation 
Calu-6 cells or HCT-116p53-/- cells were pelleted and resuspended in 
lysis buffer (10mM NaCl, 10mM MgCl2, 10mM Tris–HCl (pH 7.5), 0.5% 
NP-40, aprotinin 1 mg/ml, leupeptin 1 mg/ml, pepstatin A 1mg/ml, 
phenylmethylsulfonyl fluoride 100mg/ml). After incubation in ice for 10 
min, the extract was centrifuged for 1 min in a microcentrifuge at a 
maximum speed at 4°C and the supernatant (total extract) was frozen in 
liquid nitrogen. To isolate ribosomes and ribosomal subunits, the total 
extracts were spun at 100 000 g for 2 h on 15% sucrose cushion. After 
centrifugation, the pellet (which includes polysomes and ribosomal 
subunits) was resuspended in Loading Buffer (63mM Tris–HCl (pH 6.8), 
5% glycerol, 1% SDS, 2.5% bromophenol-blue) for western blot analysis, 
whereas the supernatant was precipitated with 10% trichloroacetic acid and 
resuspended in Loading Buffer for western blot analysis. 
 
2.12 !-H2AX quantification  
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To analyze the levels of double strand breaks (DSB) of DNA, Calu-6 
cells, HCT-116 p53-/- cells or p21DCalu-6 cells were fixed and permeabilized 
with cold (#20°C) 70% ethanol overnight, washed with 1% BSA-PBS, and 
further permeabilized with 0.25% Triton in 1% BSA-PBS for 5 min on ice, 
incubated with anti-$-H2AX antibody (dilution, 1/37.5) in 10% normal goat 
serum-1% BSA-PBS, washed with 1% BSA-PBS, and incubated with a 
secondary antibody conjugated with Alexa Fluor 488. Finally, propidium 
iodide (final concentration, 0.05 mg/ml) and RNase A (final concentration, 
0.5 mg/ml) were added. Fluorescence intensities were determined with a 
CyAn ADP Flow Cytometer (DAKOCytomation) and quantified using 
Summit Software. 
 
2.13 Clonogenic assays 
For clonogenic assay, Calu-6 cells or HCT-116 p53-/- cells were 
trypsinized, washed in PBS, and seeded in triplicate at 2,000 cells per well, 
in six-well plates. Colonies were allowed to grow for 10 days and visualized 
following washing with PBS, fixation in methanol for 30 min, washing 
again with PBS, and staining with 0.05% methylene blue for 30 min. 
Percent survival was normalized to the observed number of colonies 
generated from untreated cells. 
 
2.14 Analysis of homologous recombination frequency in vivo 
HeLa cells carrying a single integrated copy of a green fluorescent 
protein (GFP) recombination reporter construct were a gift from Prof. E. 
Avvedimento (Universita` di Napoli ‘‘Federico II,’’ Naples, Italy). This 
reporter construct contains two GFP genes: one nonfunctional GFP gene 
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mutated to contain a I-SceI cleavage site and an additional, truncated GFP 
gene that can correct the I-SceI site mutation. The I-SceI restriction 
endonuclease is used to introduce a double-strand break (DSB) in the 
reporter gene. Chromosomal repair of the reporter gene by homologous 
recombination leads to GFP expression, which is analyzed by flow 
cytometry. To analyze the DSB-induced homologous recombination, HeLa 
cells were transiently transfected with siRNA against endogenous rpL3 or 
pHA-rpL3 and the I-SceI expression vector pCAGGS-ISceI or with a 
cytomegalovirus (CMV) empty vector. 72 hours after transfection, the 
percentage of GFP-positive cells was determined with a CyAn ADP Flow 
Cytometer (DAKOCytomation) and quantified using Summit Software. 
 
2.15 NHEJ assay in vitro 
pGL3-control plasmid (Promega) was completely linearized by the 
restriction endonuclease HindIII or NarI and the linearized DNA was 
extracted from agarose gel with Gel Extraction kit (Invitrogen). Circular 
plasmid and linearized DNA was then co-transfected with pRT-RL plasmid 
into cells. The transfected cells were lysed and assayed for luciferase 
activity with Dual Luciferase Assay (Promega) (see sub-section “Dual 
luciferase assay”). Overall NHEJ capacity was calculated by firefly 
luciferase activity from cells transfected with HindIII or NarI-digested DNA 
relative to that of the intact plasmid. 
 
2.16 Statistical analysis 
The data are obtained from three independent experiments and 
presented as means ± standard deviation.  
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3. Results 
 
3.1 rpL3 upregulates p21 expression at transcriptional level 
independently from p53  
To investigate whether rpL3 controls p21 expression in a p53 deficient 
environment, we analyzed p21 mRNA and protein levels upon rpL3 
overexpression in p53-null Calu-6 cells (Cuccurese et al., 2005). The 
exogenous expression of the HA-tagged rpL3 protein resulted in a dose-
dependent increase of p21 protein and mRNA (Fig. 3.1A, B).  
To examine the possibility that p21 upregulation was due to rpL3 
controlling the p21 promoter, we performed a p21 reporter luciferase assay. 
The overexpression of rpL3, in contrast to rpL7a (Russo et al., 2005), led to 
the activation of p21 reporter in a dose-dependent manner (Fig. 3.1C). 
Control CMV-luciferase reporter activity did not change upon rpL3 nor 
rpL7a overexpression (Fig. 3.1D). 
We next investigated whether rpL3 was able to interact with p21 
promoter. Calu-6 cells were collected and ChIP analysis using rpL3 
antibody was performed. IgG antibody was used as specificity control. 
The presence of rpL3 was investigated by western blotting in the 
DNA-immunoprecipitated complexes (Figure 1E). Quantitative PCR assay 
on the samples performed with primers specific for the proximal region of 
p21 promoter (-194 to +88) (Wu et al., 2003) or control loci (3’UTR) 
showed the presence of a specific signal for p21 promoter in the DNA-rpL3 
immunocomplex. No signal was detected in the IgG control (Fig. 3.1E). 
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Figure 3.1. Role of rpL3 in the regulation of p21 expression. (A) Western Blot (WB) 
analysis of protein samples from Calu-6 cells transfected with the indicated amount of 
pHA-rpL3 with antibodies directed against HA and p21, 24 hours after transfection. (B) 
Representative RT-PCR analysis of total RNA from the same samples. !-actin was used as 
a control for RNA loading. Quantification of p21 protein and mRNA levels by 
PhosphorImager (Bio-Rad) is shown. (C and D) Analysis of the relative Firefly luciferase 
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activity, normalized to Renilla luciferase (pRL), in Calu-6 cells transiently transfected with 
p21-Luc or CMV-Luc plasmid with or without the indicated plasmids, 24 hours after 
transfection. WB analysis of protein extracts of the same samples with antibodies directed 
against HA and His. (E) WB analysis of DNA-rpL3 or DNA-IgG immunocomplexes with 
antibodies against rpL3 and IgG. Note the absence of signal in DNA-IgG immunocomplex. 
The same DNA-immunoprecipitates were subjected to quantitative PCR (qPCR) with 
primers specific for the proximal region of p21 gene promoter or control loci.  
 
3.2 NPM and SP1 modulate rpL3-dependent p21 gene promoter 
transactivation  
The absence of a direct binding between rpL3 and p21 promoter, 
observed in EMSA experiments (not shown), prompted us to search for 
rpL3-interacting regulatory proteins involved in the rpL3-mediated 
regulation of p21 transcription. We have previously reported that NPM, in a 
complex with rpL3, is required for the regulation of the rpL3 gene 
alternative splicing (Russo et al., 2011). Thus, we explored the possibility 
that the rpL3-NPM complex was involved in the transactivation of the p21 
gene transcription. ChIP experiments by using anti-rpL3, anti-NPM and IgG 
showed that both rpL3 and NPM bind to the p21 promoter, but not to a 
control region of the DNA (p21 3’UTR) (Fig. 3.2A). 
To investigate whether the interaction between rpL3 and NPM on p21 
promoter affects its activity, a reporter luciferase assay was performed while 
altering intracellular levels of NPM in cells with HA-rpL3 overexpression. 
The results demonstrated that under both physiological and supra-
physiological levels of rpL3, the overexpression of NPM did not affect the 
activity of p21 gene promoter (Fig. 3.2B). Whereas under physiological 
conditions of rpL3 expression, the NPM silencing was associated with the 
inhibition of p21 transcriptional activity as indicated by a significant 
decrease (40%) in p21 gene promoter activity (Fig. 3.2C). Of interest, the 
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rpL3 overexpression rescued the reduction of p21 transcriptional activity 
caused by NPM silencing suggesting that additional factors are required for 
the rpL3-mediated activity on p21 gene promoter. 
In the attempt to identify other proteins involved in the rpL3-mediated 
activation of p21 transcription, we focused on the possible role of Sp1, a 
protein factor that regulates p21 transcription (Koutsodontis et al., 2002). 
ChIP experiments in Calu-6 cells treated with the specific Sp1 inhibitor 
mythramycin A (MTM) (Koutsodontis and Kardassis, 2004) show that a 
specific association between Sp1 and rpL3 occurs on the p21 gene promoter 
in absence of MTM. Of interest, the presence of MTM prevents the binding 
of both rpL3 and Sp1 on the p21 gene promoter, indicating that rpL3 is able 
to bind p21 gene promoter only in the presence of Sp1 (Fig. 3.2D). 
In order to study the function of Sp1 in rpL3-dependent transactivation 
of p21 gene promoter, a reporter luciferase assay was performed in Calu-6 
cells overexpressing rpL3 and Sp1, with or without MTM treatment. Figure 
3.2E shows that in the absence of MTM, rpL3 or Sp1 overexpression 
increased the activity of p21 gene promoter, as previously observed (Cen et 
al., 2008). In addition, rpL3 and Sp1 overexpression had a synergistic effect 
on the transactivation of p21 gene promoter. Interestingly, the ability of both 
rpL3 and Sp1 to activate the transcription of luciferase was strongly reduced 
in the presence of MTM. This data suggested that the ability of rpL3 to 
activate p21 transcription requires the presence of Sp1 on the promoter. 
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Figure 3.2. Role of NPM and SP1 in the rpL3-mediatyed p21 transcriptional 
regulation. (A) WB analysis of DNA-rpL3, DNA-NPM or DNA-IgG immunocomplexes 
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with antibodies against the indicated proteins. Note the absence of signal in IgG 
immunocomplex. The same DNA-immunoprecipitates were subjected to quantitative PCR 
(qPCR) with primers specific for the proximal region of p21 gene promoter or 3’UTR 
control loci. (B) The relative Firefly luciferase activity, normalized to Renilla luciferase 
(pRL), in Calu-6 cells transiently transfected with the indicated plasmids, 24h after 
transfection. WB analysis of protein extracts from the same samples with antibodies 
directed against the HA and Flag tags. (C) The relative Firefly luciferase activity, 
normalized to Renilla Luciferase (pRL), in Calu-6 cells transiently transfected with the 
indicated plasmids, 24h after transfection. WB analysis of protein extracts from the same 
samples with antibodies directed against the HA and NPM. (D) WB analysis of DNA-rpL3, 
DNA-Sp1or DNA-IgG immunocomplexes from Calu-6 cells untreated or treated with 200 
nM of mythramycin A (MTM) for 16 hours with antibodies against rpL3 or Sp1. Note the 
absence of signal in DNA-IgG immunocomplex. The same DNA-immunoprecipitates were 
subjected to quantitative PCR (qPCR) with primers specific for the proximal region of p21 
gene promoter or control loci. (E) The relative Firefly luciferase activity, normalized to 
Renilla luciferase (pRL), in Calu-6 cells transiently transfected with the indicated plasmids 
and treated for 16h or not with 200 nM of mythramycin A (MTM), 24h after transfection. 
WB analysis of protein extracts from the same samples with antibodies directed against the 
HA and His tags.  
 
3.3 Sp1-binding boxes 3 and 4 are involved in rpL3-dependent 
transactivation of p21 gene promoter 
The proximal region of the human p21 promoter carries six GC-rich 
Sp1-binding sites (numbered 1-6 in plasmid pWP124, Fig. 3.3). To 
determine which of Sp1-binding elements mediate rpL3-responsiveness, 
Calu-6 cells were transiently transfected with pW124 or truncated plasmids 
in which two or four Sp1-binding sites were simultaneously deleted 
(pWP101 and pWPdel-Sma I) (Huang et al., 2000) in the presence or 
absence of pHA-rpL3 (Fig. 3.3). Upon the overexpression of rpL3, deletion 
of Sp1-binding sites 1 and 2 (pWP101) lead to an increase in the luciferase 
activity comparable to that obtained when all the six Sp1 binding motifs are 
present (pWP124). Additional deletion of Sp1-binding sites 3 and 4 
(pWPdel-Sma I) abrogated completely rpL3 effect on p21 gene promoter 
transactivation (Fig. 3.3). This data suggests that the region spanning from -
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60 to -101 upstream from the transcription start site, including Sp1-binding 
sites 3 and 4, corresponds to rpL3 responsive element and is involved in 
rpL3-mediated activation of p21 gene promoter.  
 
Figure 3.3. Analysis of p21 promoter regions involved in rpL3-mediated p21 
transcriptional regulation. On the left, a schematic representation of the deletion 
constructs of the p21 gene promoter used in the luciferase transfection assay. Analysis of 
the relative Firefly luciferase activity, normalized to Renilla luciferase (pRL), in Calu-6 
cells transiently transfected with the indicated constructs, 24 hours after transfection. 
Proteins from the same samples were analyzed by WB assay with antibody directed against 
the HA tag.  
 
3.4 rpL3 overexpression induces cell cycle arrest or apoptosis in 
Calu-6 cells 
In order to investigate the effect of rpL3-mediated upregulation of p21 
transcription on cell proliferation, we performed 5-bromodeoxyuridyne 
(BrdU) incorporation to monitor DNA synthesis and propidium iodide (PI) 
staining to analyze DNA content of Calu-6 cells transiently transfected with 
1 µg or 2 µg of pHA-rpL3. As expected, rpL3 overexpression induced an 
increase of p21 expression in a dose-dependent manner (Fig. 3.4A). BrdU 
incorporation in cells transfected with 1 µg of pHA-rpL3 was significantly 
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decreased versus that observed in control (about 0.7% versus 25%, 
respectively). This indicated that the enforced expression of rpL3 produced 
a strong reduction in the percentage of cells in S-phase of the cell cycle. 
Analysis of cell cycle using the counterstaining with PI indicated that the 
observed decrease of cells in S-phase was associated with an increase of cell 
population in the G1-phase of the cell cycle (about 80% versus 50% in the 
control). Notably, in the presence of higher rpL3 levels (2 "g of pHA-rpL3) 
we observed a significant increase in the sub-G1 population, indicative of 
cell death (about 21% versus 2% in the control) (Fig. 3.4A). 
To gain further insight into the mechanism by which rpL3 causes cell 
cycle arrest and apoptosis, we proceeded to perform a cell cycle analysis 
over 72 hours in Calu-6 cells transiently transfected with 1 µg or 2 "g of 
pHA-rpL3 (Fig. 3.4B). In cells transfected with 2 µg of pHA-rpL3, an 
increase in sub-G1 cell population versus control was observed at all time 
points, although the strongest effect was detected after 48 hours. At this 
time, the percentage of cells transfected with 2 "g of pHA-rpL3 in the sub-
G1 phase of the cell cycle increased approximately 7-fold as compared to 
control (about 36% versus 5%, respectively). This effect was not observed 
with 1 µg of pHA-rpL3. Transfection of cells with this amount of pHA-rpL3 
did not induce apoptosis even 72 hours after transfection. Furthermore, we 
observed a G1/S arrest at 24 and 48 hours (as already shown in Fig. 3.4A) 
and more interestingly at 72 hours the dividing ability of Calu-6 cells 
transfected with 1 "g of pHA-rpL3 was restored, as evidenced by the 
presence of a G2/M peak (Fig. 3.4B). These results suggest that rpL3 may 
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induce G1/S arrest or apoptosis depending on its concentration inside the 
cells. 
To further study the apoptotic effect of rpL3, we analyzed PARP 
protein cleavage by western blotting and reduction of mitochondrial inner 
membrane potential (#$m) by tetramethyl-rhodamine ethyl ester (TMRE) 
staining, a hallmark of mitochondrial apoptosis (Youle and Strasser, 2008), 
in Calu-6 cells transfected with 2 µg of pHA-rpL3. As expected, we 
observed increased level of cleaved PARP in cells transfected with 2 µg of 
pHA-rpL3 (Fig. 3.4C). Furthermore, Figure 3.4C shows that the percentage 
of Calu-6 cells with a physiological #$m decreased from 88% to 58% 
(control cells versus 2 µg of pHA-rpL3 transfected cells). Overall these 
results indicate that higher levels of rpL3 protein obtained with 2 µg of 
pHA-rpL3 activate apoptosis through mitochondrial pathway in Calu-6 
cells.
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Figure 3.4. Effects of rpL3-mediated upregulation of p21 gene expression on the cell 
cycle and cell viability. (A) FACS analysis of the Calu-6 cells transfected with the 
indicated plasmids after staining with FITC conjugated anti-5-bromodeoxyuridine antibody 
and counterstaining with propidium iodide, 48h after transfection. On the bottom the 
percentage of cells in different phases of cell cycle is shown. WB analysis of protein 
samples from the same samples with antibodies directed against the HA tag and p21. (B) 
Analysis of DNA content by propidium iodide staining of Calu-6 cells transfected with the 
indicated plasmids, 24h, 48h and 72h after transfection. A quantification of percentage of 
cells in sub-G1 phase is shown. (C) WB analysis of protein extracts from Calu-6 cells 
transfected with the indicated plasmids with antibodies directed against PARP, the HA tag 
and p21, 48h after transfection. The same samples were analyzed for mitochondrial 
membrane potential by TMRE staining, and fluorescence was measured by flow cytometry 
48h after transfection.  
 
3.5 Cell cycle arrest and apoptosis upon rpL3 overexpression are 
p21-dependent  
To verify that rpL3-induced cell cycle arrest or apoptosis in Calu-6 
cells occurs through a specific pathway involving p21, we examined the 
effects of rpL3 overexpression on cell proliferation and cell death after p21 
silencing. 
We performed cell cycle analysis in Calu-6 cells and p21-depleted 
Calu-6 (p21!Calu-6) cells transiently transfected with 1 µg or 2 µg of pHA-
rpL3. Figure 3.5A shows that rpL3 was unable to induce cell cycle arrest 
upon p21 depletion. In addition, as shown in Figure 3.5B, the higher dosage 
of rpL3 failed to mediate the induction of apoptosis in p21-depleted cells, 
thus demonstrating that the dual effect of rpL3 on cell cycle arrest or 
apoptosis is dependent from p21. All these results indicate that rpL3 is able 
to induce cell cycle arrest or activate the intrinsic apoptotic pathway in 
Calu-6 cells by regulating the intracellular amounts of p21.  
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Figure 3.5. Role of p21 on rpL3-mediated cell cycle arrest and apoptosis. (A and B) 
Analysis of DNA content by propidium iodide staining of Calu-6 cells transfected with the 
indicated plasmids 24h after transfection. WB analysis of protein extracts from the same 
samples with the indicated antibodies.  
 
3.6 DNA damage increased the amount of free-ribosome rpL3  
Several RPs have been showed to accumulate in response to ribosomal 
stress triggered by DNA damage (Zhang and Lu, 2009). To address the 
possibility that rpL3 could  accumulate after DNA damage, Calu-6 cells and 
HCT-116 p53-/- untreated or treated with 5-fluorouracil (5-FU) or Oxaliplatin 
(OXH) for 24 h were collected and separated by ultracentrifugation into two 
fractions; pellet, which includes polysome and ribosomal subunits, and 
supernatant, which includes free-ribosome proteins. Western blotting 
analysis of the two fractions showed that rpS19 and rpL7a remained 
exclusively associated with ribosome after exposure to the indicated drugs 
and in addition drug treatment caused a reduction of the total amount of 
rpL7a and rpS19. Of note, we observed a detectable amount of ribosome-
free rpL3 even in absence of ribosomal stress and these levels were 
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increased in the ribosome-free fraction in response to both 5-FU or OXH 
treatment  (Fig. 3.6).  
#
 
 
Figure 3.6. Specific accumulation of free-ribosome rpL3 upon DNA damage.  Calu-6 or 
HCT-116p53-/- cells untreated or treated with the indicated drugs for 24 hours were collected 
and fractionated in ribosomal and non ribosomal fractions. The two fractions were analyzed 
by WB with the indicated antibodies. The per-sample ratio of the amount of protein loaded 
onto a gel for TF, Total fraction, PF, Pellet fraction and SF, Supernantant fraction was 
1:10:1.  
 
 
3.7 rpL3 mediates ribosomal stress after DNA damage 
In order to investigate whether rpL3 could play a role in ribosomal 
stress, we analyzed proliferation and viability of Calu-6 cells and HCT-116 
p53-/- cells untreated or treated with 5-FU or OXH while silencing rpL3. Fig. 
3.7A shows that rpL3 silencing did not cause any changes in the cell phase 
distribution as compared to control. Treatment with 5-FU or OXH affected 
differently the DNA synthesis; the incorporation of BrdU in 5-FU-treated 
cells was significantly increased vs. that observed in control (about 74% vs 
32%), whereas OXH caused the lack of BrdU incorporation (2,5% vs 
control 32%). These results indicate 5-FU treatment causes cells to enter the 
S-phase but unable to complete DNA synthesis, which is also indicated by 
the reduction of cells in the G2/M phase (4% vs. control 162%). The 
exposure to OXH, however, abolished their ability to enter S-phase. 
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rpL3 silencing prevented the inhibitory effects on cell proliferation of 
both drugs despite the diverse outcomes observed, suggesting that rpL3 may 
mediate the sensitivity of the cells to drug treatment. 
To further study the rpL3 role in the apoptotic response to 5-FU or 
OXH, we analyzed the reduction of !"m by TMRE staining, in Calu-6 cells 
and HCT-116 p53-/- untreated or treated with 5-FU or OXH upon rpL3 
silencing. As expected, Figure 3.7B shows that the percentage of cells with 
impaired !"m increased notably after 5-FU or OXH treatment as compared 
to control (26% 5-FU-cells, 46% OXH-cells versus 5.5% control). 
Interestingly, rpL3 silencing resulted in a substantial decrease in apoptotic 
cells following 5-FU and OXH treatment, respectively. Furthermore, 
silencing of rpL3 caused a significant increase in colony formation 
compared to 5-FU or OXH-treated cells  (Fig. 3.7C). These results suggest 
that rpL3 may have a role in mediating cytotoxic effects of DNA-damaging 
agents in Calu-6 cells and HCT-116 p53-/- cells. 
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Figure 3.7. Effects of rpL3 on ribosomal stress (A) FACS analysis of Calu-6 cells and 
HCT-116p53-/- cells transiently transfected with the indicated siRNA and treated with the 
indicated drugs for 24h after stained with FITC conjugated anti-5-BrdU antibody and 
counterstained with PI. The percentage of cells in different phases of cell cycle is shown. 
(B) The same samples were analyzed for mitochondrial membrane potential by TMRE 
staining. (C) Staining after 10 days with methylene blue of the same samples replaced in 
drug-free medium.  
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3.8 rpL3 inhibits HR and NHEJ pathways 
Chemotherapeutic agents cause a marked accumulation of DNA 
double strand breaks (DSBs). The formation of #-H2AX foci at damaged 
site is one of the highly sensitive markers of damage induced by these 
agents (Kuo and Yang, 2008). Therefore, we performed quantification of #-
H2AX foci in 5-FU or OXH-treated in Calu-6 cells and HCT-116 p53-/- 
following rpL3 silencing. While the percentage of #-H2AX foci positive 
cells increased after 5-FU or OXH exposure in the control, both 5-FU and 
OXH caused less accumulation of #-H2AX foci when rpL3 was silenced 
(Fig. 3.8A). Analysis of homologous recombination frequency in vivo and 
NHEJ assay in vitro after 5-FU or OXH exposure showed that both major 
pathways were upregulated when rpL3 was silenced and downregulated 
when rpL3 was overexpressed (Fig. 3.8B, C and D). These results suggest 
that accumulation of rpL3 after exposure to the chemotherapeutics was 
responsible for the inhibition of both DNA repair pathways. 
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Figure 3.8. Effect of rpL3 silencing on HR and NHEJ pathways (A) #H2AX 
quantification in Calu-6 cells or HCT-116p53-/- cells untreated or treated with the indicated 
drugs and transiently transfected with the indicated siRNAs by staining with an anti-
#H2AX monoclonal antibody followed by secondary fluorescein-conjugate antibodies. (B) 
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HeLa cells containing the DR-GFP reporter constructs integrated into the genome were 
transiently transfected with a plasmid expressing the I-SceI enzyme and the indicated 
siRNAs. 48h later, cells were assessed for GFP expression by flow cytometry. (C) Calu-6 
cells transiently transfected with pGL3-luciferase linearized by the restriction endonuclease 
HindIII or NarI with the indicated siRNAs for 48h were analyzed for the relative luciferase 
activity, normalized against Renilla Luciferase (pRL). (D) #H2AX quantification in Calu-6 
cells or HCT-116p53-/- cells untreated or treated with the indicated drugs and transiently 
transfected with the indicated siRNAs by staining with an anti-#H2AX monoclonal 
antibody followed by secondary fluorescein-conjugate antibodies. 
 
3.9 p21 partially mediates rpL3 effects on drugs sensitivity 
p21 plays a significant role in several aspects of the DNA damage 
response. It has been reported that p21 is upregulated after low levels of 
DNA damage. However, it is known that p21 downregulation is required to 
induce apoptosis when the extent of DNA damage is not reparable 
(Cazzalini et al., 2010). Having shown that overexpressed pL3 was able to 
regulate p21 expression independently of p53, we next investigated whether 
this regulation also occurs after treatment with DNA damaging drugs. ChIP 
experiments showed that rpL3 was able to bind p21 promoter following both 
5-FU and OXH treatment (Fig. 3.9A and B). Reporter luciferase assay 
shows that treatment with 10 µM of 5-FU or OXH caused an activation of 
p21 promoter and increased p21 protein levels, restored upon rpL3 
silencing, suggesting a positive role of rpL3 in the transcriptional activation 
of p21 upon mild DNA damage. In contrast, 100 µM of 5-FU or OXH 
diminished p21 gene promoter transactivation and protein levels, whereas 
silencing of rpL3 attenuated the p21 transcriptional repression (Fig. 9C). 
Analogous experiments were performed in HCT-116p53-/- with the same 
results (Fig. 3.9D). 
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Figure 3.9. Role of rpL3 in the regulation of p21 expression in response to drugs 
treatment. (A and B) WB analysis of protein samples from DNA-rpL3 or DNA-IgG 
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immunocomplexes from Calu-6 cells or HCT-116p53-/- cells treated with the indicated drugs 
for 24h with antibody against rpL3. Note the absence of signal in DNA-IgG 
immunocomplex. The same DNA-immunoprecipitates were subjected to quantitative PCR 
(qPCR) with primers specific for the proximal region of p21 gene promoter or control loci. 
(C and D) WB analysis of protein extracts from Calu-6 or HCT-116p53-/- cells transiently 
transfected with the indicated plasmids or siRNAs and treated or not with the indicated 
drugs for 24h with the indicated antibodies. Analysis of the relative Firefly luciferase 
activity, normalized to Renilla Luciferase (pRL) in the same samples.   
 
To investigate whether the mechanism by which rpL3 sensitizes cells 
to chemotherapeutic treatment occurs through a pathway involving p21, we 
measured DSBs accumulation after 5-FU or OXH exposure in p21-depleted 
Calu-6 cells while altering rpL3 levels. Figure 3.10A shows that rpL3 
silencing prevented accumulation of DSBs after drugs treatment in the 
presence of physiological levels of p21, but not when p21 was silenced. Of 
note, rpL3 overexpression was responsible for increased percentage of cells 
with DSBs regardless of p21 status, and exerted an additive effect in 
combination with 5-FU and OXH treatment (Fig. 3.10B). These results 
indicate that rpL3 is able to modulate DNA damage repair in part by 
regulating the intracellular amount of p21. However additional mechanisms 
that sensitize cells to chemotherapeutic drugs are also required. 
 
Figure 3.10. Role of p21 in rpL3-mediated regulation of drugs sensitivity. (A and B) 
#H2AX quantification in Calu-6 shRNA Ctr cells or Calu-6 shRNA p21 cells transiently 
transfected with the indicated plasmid and siRNAs by staining with an anti-#H2AX 
monoclonal antibody followed by secondary fluorescein-conjugate antibodies. 
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4. Discussion 
The nucleolus appears to provide a link between ribosome subunit 
biosynthesis, cell cycle progression and stress signaling.  
In eukaryotes, ribosome biogenesis is a complex process that requires 
a number of coordinated events prior to nuclear export of the mature 
subunits to the cytoplasm (Fromont-Racine et al., 2003; Kressler et al., 
2009) Interestingly, the protein content of the nucleolus is dynamic and 
alters under stress condition, revealing a complex reorganization of the 
nucleolus under the stress response. Recent studies have shed new light on 
the mechanisms underlying the regulation of these events and have revealed 
new connections between ribosome biogenesis and cell cycle. In fact, 
perturbation of ribosome assembly has recently emerged as a relevant cell 
cycle arrest or apoptosis-promoting pathway. The signaling pathways able 
to connect these two processes have long been relatively unknown. 
However, more recently the role of the RPs-Mdm2-p53 stress response 
pathway in the coregulation of these events has been widely demonstrated 
(Zhang and Lu, 2009). Alterations in processes such as rRNAs synthesis, 
rRNAs modification and RPs imbalance produce alterations in ribosome 
biogenesis and result in ribosomal stress. In response to this event several 
RPs translocate to the nucleoplasma and bind to Mdm2, thus promoting p53 
stabilization and subsequent p53-mediated cell cycle arrest or apoptosis 
(Amsterdam et al., 2004).  
Several p53-independent pathways that require nucleolar proteins, 
such as ARF, NPM or free RPs have been descrive (Donati et al., 2012; 
Sherr, 2006). These findings provide a rational basis for the use of drugs that 
specifically impact ribosome biogenesis for the treatment of cancers lacking 
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functional p53 and extend the scenario of mechanisms involved in the 
relationship between cell growth and cell proliferation. 
In this thesis, I unraveled a new extraribosomal function for human 
rpL3 in addition to its role in the regulation of the alternative splicing of its 
own gene. Specifically, I demonstrated that rpL3, when overexpressed, is 
able to induce cell cycle arrest or apoptosis in Calu-6 cells by modulating 
p21 level thorugh a p53-independent pathway. To our knowledge the 
present study demonstrates for the first time a direct role of an RP, 
specifically rpL3, in the regulation of p21 transcription.  
I started my project with the observation that rpL3, when 
overexpressed, was able to positively modulate the activity of p21 promoter. 
Moreover, ChIP analysis on Calu-6 cells showed that rpL3 interacts with 
p21 proximal promoter (-194 to +88) (Figure 3.1). In an attempt to 
understand the mechanism of the rpL3-mediated upregulation of p21 
expression, I focused on the identification of protein partners of rpL3 
protein involved in this activity. It is known that NPM is able to indirectly 
bind to p21 proximal promoter and activate its transcription (Wanzel et al., 
2008). Furthermore, our previous results demonstrated that NPM is able to 
interact directly with rpL3, and that this interaction is functional to the 
regulation of the rpL3 protein levels inside the cells (Russo et al., 2011). 
Starting from this knowledge, a possible involvement of this complex in the 
rpL3-induced p21 transactivation has been hypothesized. ChIP experiments 
established that NPM and rpL3 are present in a reciprocal DNA-
immunoprecipitate indicating that both proteins are recruited on p21 
proximal promoter (Figure 3.2A). Data from protein overexpression 
indicated that NPM alone or in combination with rpL3 did not affect the 
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activity of p21 promoter, while NPM silencing markedly reduced the 
constitutive and rpL3 induced transactivation of p21 promoter (Figures 3.2B 
and C). Taken together, these results clearly demonstrate that NPM 
represents a positive regulator of rpL3-mediated transactivation of p21 gene, 
although it is not a crucial player in this event.  
It is well known that p21 proximal promoter contains six Sp1 binding 
sites and that Sp1 is able to transcriptionally regulate the activity of different 
genes including those involved in the regulation of the cell cycle 
(Koutsodontis et al., 2002). Specifically, Sp factors have been proposed to 
be essential for transactivation of the p21 promoter by members of the p53 
family proteins. I demonstrated that rpL3 associates in vivo with Sp1 on the 
p21 proximal promoter only in absence of MTM. Although treatment with 
MTM did not prevent the formation of a complex between rpL3 and Sp1 
into the cells, it hindered its recruitment on p21 promoter (Figure 3.2D). 
Data from rpL3 and Sp1 overexpression in Calu-6 cells in the absence of 
MTM indicated that expression of Sp1 in combination with rpL3 strongly 
increased rpL3-mediated p21 transactivation. These findings together with 
the observation that rpL3, even in excess, was unable to transactivate p21 
promoter in the presence of MTM strongly indicated that the binding of Sp1 
to the proximal p21 promoter region is essential for the rpL3 mediated 
transactivation of p21 promoter. Thus, we propose that Sp1 is the key 
component of rpL3-mediated p21 transactivation. In fact, Sp1 binding to GC 
boxes 3 and 4 is a prerequisite for rpL3 recruitment on p21 proximal 
promoter (Figure 3.3).  
In light of these results, we propose a working model in which 
overexpression of rpL3 leads to a formation of a multiprotein complex 
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containing at least rpL3, Sp1 and NPM on the proximal region of p21 
promoter with consequent upregulation of p21 expression. This upregulation 
leads to a dual outcome, either arresting the cell cycle progression at G1/S 
phase or promoting apoptosis. The cells fate depends on the levels of rpL3 
and p21 protein (Figure 3.4A). To better understand the dynamics of these 
events, time-course analysis of the DNA content in Calu-6 cells transfected 
with different amounts of pHA-rpL3 was performed. Interestingly, we 
observed that 1 µg of pHA-rpL3 induced a reversible G1/S arrest of the cell 
cycle; in fact, Calu-6 cells restored their capability to progress through the 
G1/S transition at 72h after transfection. Instead, transfection with 2 µg of 
pHA-rpL3 triggered mitochondrial apoptosis even at 24h after transfection 
(Figures 3.4B and C). Moreover, we showed that p21 is essential for both 
rpL3-induced cell cycle arrest and mitochondrial apoptosis, since stably 
depletion of p21 in Calu-6 cells completely abolished both events (Figure 
3.5). Taken together, these data demonstrate that rpL3 plays an important 
role in the activation, through modulation of p21 levels, of two independent 
pathways; on one hand, reversible arrest of cell cycle, and on the other hand, 
mitochondrial apoptosis. In light of these observations, our working model 
predicts that the intracellular levels of rpL3 could be crucial in regulating 
the hierarchy of interactions of p21 with multiple factors, leading to the 
assembly of specific protein complexes which could trigger two distinct 
effects (Russo et al., 2013). 
These data are in complete agreement with recent findings 
demonstrating a much more complex scenario than had been expected 
regarding p21 role in the regulation of cell cycle and DNA damage repair. In 
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particular, p21 has been proven to also exert a proapoptotic function under 
certain conditions in specific systems beyond its well-known role in growth 
inhibition. Notably, in most of these cases, the cellular systems used express 
a non-functional p53 isoform. The mechanism by which p21 may promote 
apoptosis is poorly understood and different working models have been 
proposed. However, the common assumption is that the cellular activities of 
p21 are tightly regulated by multiple factors that seem to be specific for each 
function in different systems. For example, the interaction of p21 with 
PCNA is implicated in sodium butyrate-induced apoptosis (Chopin et al., 
2004), other studies indicate that the modulation of proapoptotic or 
antiapoptotic genes is responsible for p21-induced apoptosis (Hsu et al., 
1999; Wu et al., 2002). 
Next, I evaluated whether rpL3 could have a role in the ribosomal 
stress in response to DNA damage, as reported for other RPs. Analysis of 
ribosome and free-ribosome fractions after exposure to chemotherapeutic 
agents 5-FU and OXH revealed an extraribosomal accumulation of rpL3 
(Fig. 3.6). Evaluation of their effects on proliferation and viability upon 
rpL3 silencing showed that both chemotherapeutic agents require the 
presence of rpL3 to exert their cytotoxic effects (Fig. 3.7 and 3.8). Two 
main DNA repair pathways, homologous recombination and NHEJ, 
cooperate to repair DNA DSBs, induced by 5-FU and OSH. Then, I 
investigated the ability of rpL3 to modulate these two processes in drug-
treated cells. My data show that rpL3 overexpression significantly decreased 
the activity of both pathways, while rpL3 silencing improved their 
effectiveness (Fig. 3.8). The results described above indicate that rpL3, by 
hindering both homologous recombination and NHEJ repair processes, has 
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the potential to inhibit recovery of mildly and seriously damaged p53-null 
tumor cells after drug treatment and to increase the susceptibility of tumor 
cells to chemotherapy. 
 p21 exerts a key role in the response of cells to genotoxic stress. Our 
understanding of p21 functions has greatly improved. In addition, it has also 
elucidated the dual role of p21 in DNA damage repair. Although the role of 
p21 in this context is still controversial, recent lines of evidence support a 
positive role for p21 in DNA repair. p21 function in response to DNA 
damage is modulated by the extent of genotoxic lesions, through either 
upregulation of downregulation of the protein: low levels of DNA lesions 
cause increasing of p21, and induce cell cycle arrest, in contrast, after 
extensive DNA damage, p21 downregulation allow cells to undergo 
apoptosis. Data from ChIP experiments and reporter luciferase assays 
showed that rpL3 is critical for regulating both upregulation and 
downregulation of p21 at transcriptional level following different extent of 
DNA damage (Fig. 3.9). 
 Moreover, I showed that while p21 is essential for DNA repair, since 
stable depletion of p21 in Calu-6 cells completely abolished the rescue of 
!H2AX accumulation after drugs exposure, overexpression of rpL3 
increased the DNA damage suggesting a p21-independent role in the 
inhibition of DNA DSBs repair as a novel mechanism of action by which 
rpL3 affects tumor cells (Fig. 3.10). 
Data reported in this thesis indicate that rpL3 is a critical regulator of 
p21 expression in response to ribosomal stress. rpL3 is able to both 
upregulate and downregulate p21 at transcriptional level dependent on the 
extent of DNA damage, triggering two distinct pathways; cell cycle arrest or 
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mitochondrial apoptosis in a p53-independent manner. Although the 
molecular details underlining these mechanisms remain to be clarified, I 
speculate that determinant of cell fate after DNA damage are the molecular 
partners of rpL3 in mediating regulation of p21 expression.  
At the present, the challenge is to identify rpL3 molecular partners 
involved in the cellular response to rpL3 accumulation. This will help to 
elucidate the role of RPs in the control of cell cycle and cell death through 
p21-dependent and independent molecular pathways. 
It is worth noting that the rpL3 gene is located on chromosome 22q13. 
Allelic loss on 22q13 is a common somatic alteration in several neoplastic 
processes including breast and colorectal cancer. However, no tumor 
suppressor gene on this chromosome region involved in these neoplasms has 
been identified thus far (Castells et al., 2000). The identification of the 
cellular targets of chemoterapeutic drugs is an important challenge for the 
improvement of therapy regimens in the future.  
Understanding the mechanism by which cytotoxic agents cause cell 
death and by which tumors become resistant to chemotherapy is an essential 
step towards predicting or even overcoming that resistance and improving 
the overall response rate. 
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ABSTRACT
Alternative pre-mRNA splicing (AS) is a major mech-
anism that allows proteomic variability in eukaryotic
cells. However, many AS events result in mRNAs
containing a premature termination codon, which
are degraded by nonsense-mediated mRNA decay
(NMD) pathway. We have previously demonstrated
that human rpL3 autoregulates its expression
through the association of AS with NMD. In fact,
overexpression of rpL3 promotes downregulation
of canonical splicing and upregulation of alternative
splicing that produces an NMD-targeted mRNA
isoform. The result of these events is a decreased
production of rpL3. We have also identified hetero-
geneous nuclear ribonucleoprotein (hnRNP) H1 as a
splicing factor involved in the regulation of rpL3 al-
ternative splicing and identified its regulatory cis-
elements within intron 3 transcript. Here, we report
that NPM and KHSRP are two newly identified
proteins involved in the regulation of rpL3 gene ex-
pression via AS-NMD. We demonstrate that hnRNP
H1, KHSRP and NPM can be found associated, and
present also in ribonucleoproteins (RNPs) including
rpL3 and intron 3 RNA in vivo, and describe protein–
protein and RNA–protein interactions. Moreover, our
data provide an insight on the crucial role of hnRNP
H1 in the regulation of the alternative splicing of the
rpL3 gene.
INTRODUCTION
Alternative splicing (AS) is an important mechanism of
gene expression control, through which an individual
gene gives rise to different mRNAs encoding distinct
proteins, thus allowing functional and genetic variability
(1). In addition to the canonical splice elements, auxiliary
non-splice site RNA sequences have been identified and
are located in both introns and exons. These additional
elements are needed for a proper splicing and regulation of
the process. They may function as enhancers or silencers
of the splicing reaction, and may influence recognition
and usage of the splice sites by the splicing apparatus
through the binding of specific regulatory proteins (2).
These proteins include members of the serine–
arginine-rich (SR) proteins, the heterogeneous nuclear
ribonucleoprotein (hnRNP) family and other RNA
binding proteins (3). The SR proteins represent a family
of highly conserved trans-acting factors that usually
induce splicing, whereas the hnRNP proteins can affect
the splicing depending on the interacting cis-elements
and on the gene context (4,5). Moreover, in some case,
the result of a splicing reaction is determined by the an-
tagonistic action of hnRNP and SR proteins since they are
able to recognize and bind to a composite regulatory
element generated by the overlapping of enhancer and
silencer elements (6).
AS can also control gene expression quantitatively by
generating unproductive mRNAs that are targeted for
degradation by nonsense-mediated decay (NMD) (7).
NMD is a surveillance pathway that detects and selective-
ly degrades aberrant mRNAs harboring a premature ter-
mination codon (PTC), thus preventing the production of
truncated polypeptides potentially deleterious to the cell.
NMD is highly conserved in eukaryotes; many studies
have dissected machinery components, and the issue of
its localization in a cell compartment has been thoroughly
discussed (8,9 and references therein). The process
regulating gene expression through AS-NMD association
has been defined Regulated Unproductive Splicing and
Translation (RUST) (10).
Although the mechanisms of the AS have been exten-
sively studied, the complex regulation of such process is
still an issue. The complexity of the regulation pathways is
due to an intricate and dynamic network of protein–
protein and RNA–protein interactions. Changes in the
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activity, number and association of splicing factors in the
network can modify the selection of the splice site and
the activity of the splicing machinery, and therefore the
splicing pattern of the target pre-mRNA.
The regulation of pre-mRNA splicing plays an import-
ant role in human pathologies (11). Impairment of the AS
is closely related to some disease mechanisms as in the case
of spinal muscular atrophy and myotonic distrophy.
Recently, new therapies aimed to correct defects arising
in pre-mRNA splicing, the so-called ‘splice-correction’ or
‘splice-modulation’ therapies, have been developed (12).
The accuracy of the AS depends on the stoichiometry
and interactions of positive and negative regulatory
proteins. Consequently, the identification of the proteins
participating in the modulation of the AS is an essential
step to study the many aspects of gene expression.
Data from several laboratories demonstrate that some
alternative isoforms of mRNA-encoding ribosomal
proteins (rp) are NMD substrates. In Caenorhabditis
elegans, it has been shown that the AS of genes rpL3,
rpL12, rpL10 and rpL7 gives rise to aberrant mRNA
isoforms, which contain a PTC resulting from an incom-
plete intron removal, and are natural substrate of NMD
(13). The AS event appears conserved in humans and in
other mammals on rpL3 and rpL12 genes. In fact, we have
previously demonstrated that human rpL3 gene transcript
gives rise to a canonical mRNA and to an alternative
mRNA isoform containing a PTC targeted to decay by
NMD. rpL3 is able to modulate its own production via a
negative feedback loop. In fact, rpL3 overexpression
results in a decreased level of the canonically spliced
mRNA, and an increased production of the alternatively
spliced isoform (14). We have also identified the hnRNP
H1, as a transacting factor able to interact in vitro and
in vivo with rpL3 and with intron 3 transcript of the rpL3
gene. Our data demonstrated that hnRNP H1 is involved
in promoting the AS of human rpL3 pre-mRNA. In
addition, we have identified and characterized the
cis-acting regulatory elements, G runs, involved in
hnRNP H1-mediated regulation of splicing (15). In the
present study, we analyze the role of hnRNP H1 in the
rpL3 autoregulatory loop, and we report the identification
of two new regulatory proteins, KHSRP (K-homology
splicing regulatory protein, also known as KSRP) and
NPM (Nucleophosmin, also known as B23, numatrin or
NO38), which exhibit opposite effects on the splicing
reaction of rpL3 pre-mRNA. Our data contribute to
shed light on protein–protein and RNA–protein inter-
actions within putative RNP complexes involved in the
modulation of splicing of the rpL3 gene.
MATERIALS AND METHODS
Cell cultures, transfections and drug treatment
Human cell line HeLa was cultured in Dulbecco’s
Modified Eagle’s Medium (DMEM) with glutamax
(Invitrogen, Carlsbad, CA, USA) supplemented with
10% fetal bovine serum (FBS), 2mM L-glutamine and
penicillin–streptomycin 50U/ml.
L3–8 cell line, derived from rat PC12 Tet-Off cell line
and conditionally overexpressing rpL3 upon doxycyclin
removal (14), was grown in DMEM supplemented with
5% fetal calf serum (FCS), 10% horse serum, 2mM
L-glutamine and 100 mg/ml G418 (Invitrogen), hygromycin
200 mg/ml (USB, Santa Clara, CA, USA) and doxycyclin
10 ng/ml (Sigma, St Louis, MO, USA). The expression of
HA-rpL3 was induced upon removal of doxycyclin.
siRNA transfections were performed in HeLa cells
(1! 106 cells, 6mm well plate) at a concentration of
150 nM by using Oligofectamine Reagent (Invitrogen) ac-
cording to the manufacturer’s instructions.
Plasmids were transfected in L3–8 cell line or in HeLa
cells (2.5! 106 cells, 6mm well plate) by using
Lipofectamine 2000 (Invitrogen) according to the manu-
facturer’s instructions. Twenty-four hours after DNA or
siRNA transfections, cells were treated with 100 mg/ml
cycloheximide (CHX) for 4 h to block NMD. Then,
RNA and proteins were extracted by using the Trizol pro-
cedure (Invitrogen) for RT–PCR analysis and western
blot, respectively. Transfection efficiency was assessed by
cotransfecting a GFP-expressing vector and normalizing
RNA levels against GFP mRNA levels (data not shown).
DNA constructs and production of recombinant proteins
The cDNA of NPM was obtained by RT–PCR from
HeLa cells using the primers 50-ATGGAAGATTCGAT
GGAC-30 (forward) and 50-TTAAAGAGACTTCCTCC
A-30 (reverse), and cloned into a version of the eukaryotic
expression vector pcDNA4/HisMax C (Invitrogen) con-
taining the HA epitope, into the prokaryotic expression
vector pRSET-A (Invitrogen) containing the Histidine
tag, and in the prokaryotic expression vector pGEX4T3
(GE Healthcare, Waukesha, WI, USA). The cDNA of
hnRNP H1 was obtained by RT–PCR from HeLa cells
using the primers 50-ATGATGTTGGGCACGGAA-30
(forward) and 50-CTATGCAATGTTTGATTGAAAA-30
(reverse), and cloned into the prokaryotic expression
vector pRSET-A. The plasmids encoding GST-hnRNP
H1, GST-rpL3, HA-hnRNP H1, Flag-KHSRP and
pGEM4Z-Int3 were already available (15,16).
The recombinant proteins GST-hnRNP H1, GST-rpL3,
GST-rpL7a and GST were expressed in Escherichia coli
and purified by using glutathione Sepharose 4B beads
according to the manufacturer’s instructions (GE
Healthcare). The recombinant proteins His-NPM,
His-hnRNP H1 and His-rpL7a were expressed in E. coli
and purified by the nickel–nitrilotriacetic acid (Ni–NTA)-
Agarose chromatography according to the manufacturer’s
instructions (Qiagen, Valencia, California). His-tagged
KHSRP was expressed in Sf9 cells using the Baculovirus
system (Baculogold, BD Biosciences) and purified by
Ni–NTA-Agarose chromatography (16).
RNA interference
The target sequences of small interfering RNAs (siRNA)
in hnRNP H1 were: 50-GGAAATAGCTGAAAAGGC
T-30 and 50-CCACGAAAGCTTATGGCCA-30
(Ambion, Foster City, CA, USA). The siRNAs targeting
NPM and KHSRP were purchased from Santa Cruz
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Biotechnology (Santa Cruz Biotechnology, Santa Cruz,
CA, USA, sc-29771, sc-44831).
GST pull down
For GST pull-down assay, 50 mg of the fusion protein or
GST control, as bait were immobilized on glutathione-
Sepharose beads and incubated with 20 mg of the recom-
binant protein of interest in pull-down buffer (50mM
Tris–HCl, pH 7.5, 0.4mM EDTA, 150mM NaCl, 10%
glicerol, 1% NP-40, 1mM sodium-ortovanadate, 50mM
NaF, 5mM DTT and Protease Inhibitor Mix 1X) at 4"C
for 1.5 h. The beads were washed extensively and boiled in
SDS sample buffer. The eluted proteins were loaded on
12% SDS–PAGE and analyzed by western blotting.
Immunoprecipitation and western blotting
For immunoprecipitation assay, 1mg of HeLa whole-cell
lysate was incubated with 30 ml of protein A/G agarose
beads coated with 5 mg of anti-NPM or anti-KHSRP
(Santa Cruz Biotechnology sc-47725, sc-33031) at 4"C
for 12 h. The beads were washed and boiled in the SDS
sample buffer. The eluted proteins were loaded on 12%
SDS–PAGE and detected by western blotting. Aliquots of
protein samples (30 mg) were resolved by 12% SDS–gel
electrophoresis and transferred into nitrocellulose filters.
The membranes were blocked in PBS, 0.1% Triton and
5% dry milk for 2 h, and then challenged with anti-NPM,
anti-KHSRP, anti-hnRNP H1, anti-HA, anti-Flag (Santa
Cruz Biotechnology sc-10042, sc-57592 and sc-807) and
anti-rpL3 (Primm, Milan, Italy). The proteins were
visualized with enhanced chemiluminescence detection
reagent according to the manufacturer’s instructions
(Pierce, Rockford, IL, USA).
RNA pull-down assay
RNA pull-down assay was carried out by using adipic acid
dehydrazide beads. Briefly, 20 mg of intron 3 RNA,
transcribed in vitro from pGEM4Z-Int3, were placed in
a 400 ml reaction mixture containing 100mM NaOAc
pH 5.2 and 5mM sodium m-periodate (Sigma), incubated
for 1 h in the dark at room temperature, ethanol
precipitated and resuspended in 100 ml of 100mM
NaOAc, pH 5.2. Then, 300ml of adipic acid dehydrazide
agarose beads 50% slurry (Sigma) equilibrated in 100mM
NaOAc pH 5.2 were added to this mixture, which was
then incubated for 12 h at 4"C on a rotator. The beads
with the bound RNA were pelletted, washed twice with
1ml of 2M NaCl and equilibrated in washing buffer
(5mM HEPES pH 7.9, 1mM MgCl2, 0.8mM magnesium
acetate). The intron 3 RNA was then incubated with 50 mg
of each recombinant protein for 30min at room tempera-
ture in a final volume of 0.6ml. The beads were then
washed four times in 1.5ml of washing buffer. Bound
proteins were eluted in SDS sample buffer loaded on a
12% gel for SDS–PAGE and analyzed by western
blotting.
RNP immunoprecipitation assay
For RNP immunoprecipitation assay (RIPA), HeLa cells
(2! 106 cells) were lysed in 600 ml RIPA buffer 1! (10mM
Tris–HCl pH 7.5, 150mM NaCl, 0.1mM EDTA, 1mM
Na ortovanadate, 0.05M NaF, 0.5% NP-40) with
protease inhibitors mix 1! (Roche, Basel, Switzerland)
for 60min on ice, and then centrifuged at 10 000 g at
4"C for 15min. The supernatant was subjected to a
pre-clearing step in which it was incubated with 50 ml of
protein A/G plus agarose for 1 h at 4"C. The pre-cleared
cell extracts were then incubated with antibodies specific
for each protein (Santa Cruz Biotechnology) overnight at
4"C. Protein A/G plus agarose beads (50 ml of 50% slurry)
were then added and the mix was incubated for 1 h at 4"C
with gentle shaking and centrifuged. The immunopre-
cipitates were suspended in 100 ml TES buffer (10mM
Tris–HCl pH 7.5, 0.5mM EDTA, 0.5% SDS), incubated
at 65"C for 10min and centrifuged for 1min at 10 000g.
Ten microliters of the supernatant were stored as
immunoprecipitated samples and subsequently
fractionated by SDS–PAGE to be analyzed by western
blotting. RNA was extracted from 90 ml using the Trizol
procedure (Invitrogen).
RT–PCR
For RT–PCR analysis, 1 mg of total RNA was reverse
transcribed into cDNA with the random hexamers tech-
nique using 200U of Superscript II RNAse H# Reverse
Trancriptase (Invitrogen). The reaction was carried out at
42"C for 50min and was terminated by heating to 75"C
for 15min. Ten of the 40 ml of reaction mix were PCR
amplified in a final volume of 50 ml, using 5 mM of each
specific primer, 10mM dNTPs and 0.5U of Taq DNA
polymerase (Invitrogen). Typically, 25–30 cycles of amp-
lification were performed. The primers were: rpL3-a 50-CT
CCGCTGGGCTCTGCCC-30 (forward) and 50-CTTCAG
GAGCAGAGCAGA-30 (reverse); rpL3-c 50-GGGCATT
GTGGGCTACGT 30 (forward) and 50-GTAAAGGCCT
TCTTCTTAG-30 (reverse); and b-actin 50-GGCACCACC
TTCTACA-30 (forward) and 50-CAGGAGGACAATGA
T-30 (reverse).
In separate experiments, we ascertained that the cycle
number was within the linear range of amplifications.
PCR products were visualized on 1% agarose gel con-
taining the fluorescent Vistra Green dye (15). The
labeling intensity of the PCR product, which is linear to
the amount of DNA, was quantified using the
PhosphorImager (Bio-Rad, Haercules, CA, USA).
RESULTS
Interactions between NPM, KHSRP, hnRNP H1 and
rpL3 in vivo and in vitro
We have identified, by a proteomic analysis in a previous
study, proteins associated to rpL3 and/or to intron 3 tran-
script of the rpL3 gene, and we focused our studies on
proteins involved in RNA processing as putative compo-
nents of a RNP complex including rpL3 and mediating
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alternative splicing of the rpL3 pre-mRNA. Mass spec-
trometry results from GST pull-down experiments using
GST-rpL3 as bait demonstrated that NPM is one of
the proteins able to interact with rpL3 in vitro.
Conversely, KHSRP was not found associated to rpL3.
However, data obtained from RNA pull-down experi-
ments indicate that KHSRP is able to interact with the
intron 3 transcript of the rpL3 gene (15). Thus, we asked
whether NPM and KHSRP could be part of a RNP
complex including rpL3 through a direct or indirect inter-
action in vivo, by performing co-immunoprecipitation
assays.
Figure 1 shows the results of the experiments in which
NPM and KHSRP were specifically immunoprecipitated
from HeLa cells extracts by using antibodies against the
endogenous proteins. Immunoprecipitated proteins were
separated by SDS–PAGE and the presence of NPM and
KHSRP was investigated by western blotting in the recip-
rocally immunoprecipitated complexes. The results of
these experiments showed that NPM and KHSRP were
coimmunoprecipitated, thus indicating that they can asso-
ciate in vivo. Furthermore, a specific signal for rpL3
appeared both in NPM as well as in KHSRP
immunocomplexes. These data suggest that rpL3 is able
to interact in vivo with both proteins. Since we have pre-
viously demonstrated that hnRNP H1 is found included in
a complex with rpL3 and is involved in the regulation of
rpL3 gene alternative splicing (15), we looked for hnRNP
H1 in NPM and KHSRP immunoprecipitated complexes.
The presence of signal for hnRNP H1 in both immunopre-
cipitates was consistent with a specific association between
NPM, KHSRP and hnRNP H1. A control
immunoprecipitate obtained with anti-IgG antibodies
did not give any signal, when probed with anti-NPM,
anti-KHSRP, anti-rpL3 or anti-hnRNP H1 (Figure 1);
for a further control, see Supplementary Figure S1. In
the light of these results, it is plausible to hypothesize
that NPM, KHSRP, hnRNP H1 and rpL3 are associated
in a single quaternary complex; alternatively, NPM and
KHSRP could be part of independent protein
complexes, including or not rpL3, to which they are re-
cruited through different combination of protein–protein
interactions.
In an attempt to define a RNP complex including rpL3,
we investigated protein–protein interactions that rpL3
protein partners may establish within the complex. To
this aim, we performed GST pull-down assays by using
purified recombinant proteins. His-tagged proteins were
tested for their ability to bind to immobilized
GST-tagged proteins. GST-tagged proteins, and GST as
control, were immobilized using GSH-sepharose beads
and incubated with purified His-tagged proteins.
Western blot analysis was performed on each pull-down
sample. Figure 2 shows that His-hnRNP H1 was present
in the pull-down preparation of GST-NPM, but not in
those of GST-rpL3 or GST; His-NPM was detected in
the pull-down preparations of GST-rpL3, GST-hnRNP
H1, but not in that of GST; and His-KHSRP was
revealed in the pull-down preparations of GST-rpL3 and
GST-hnRNP H1, but not in those of GST-NPM or GST.
These results indicate that although a direct interaction
between rpL3 and hnRNP H1 has not been observed,
rpL3 and hnRNP H1 are able to interact directly with
NPM and KHSRP, while NPM and KHSRP are not
able to interact directly in the in vitro assay. No inter-
action whatsoever was detected with GST-rpL7a used as
a further control (data not shown).
Interactions between KHSRP, NPM, hnRNP H1 and
the intron 3 transcript in vivo and in vitro
Mass spectral analysis of our previous RNA pull-down
experiments revealed that KHSRP was able to interact
with intron 3 transcript of rpL3 gene in vitro (15). To
confirm this interaction in vivo, we performed RNA
affinity immunoprecipitation experiments. We specifically
immunoprecipitated KHSRP, and hnRNP H1 as con-
trol, from HeLa cell extracts by using monoclonal
antibodies against the endogenous proteins and searched
for the intron 3 transcript in the RNA–protein immuno-
precipitate complex (Figure 3A). Amplification of the
signal corresponding to the intron 3 of rpL3 transcript,
but not of rpL7a gene transcript, by RT–PCR indicated
that KHSRP was able to bind with rpL3 pre-mRNA. The
absence of signal in the immunoprecipitate with anti-IgG
confirmed the validity of this assay.
Although NPM was not found associated to the intron
3 transcript in vitro previously (15), we wondered
whether this interaction can occur in vivo. To this aim,
we specifically immunoprecipitated NPM from HeLa
cell extracts by using monoclonal antibodies against
the endogenous NPM. Analysis of RNA extracted
from the immunoprecipitate complex demonstrates that
NPM is able to precipitate the intron 3 transcript
(Figure 3A).
Next, in order to establish whether one or more among
the identified proteins was able to interact directly with
intron 3 RNA, or whether additional factors were
required, we performed RNA pull-down experiments by
anti-rpL3
anti-hnRNP H1 
anti-NPM
NP
M
anti-KHSRP
IgG KH
SR
P
IgG
IP antibodies
anti-NPM
anti-hnRNP H1 
anti-rpL3 
anti-KHSRP
a7Lpr-itnaa7Lpr-itna
Figure 1. In vivo binding of NPM, KHSRP, hnRNP H1 and rpL3.
NPM or KHSRP were specifically immunoprecipitated from HeLa
cells extracts with antibodies against the endogenous NPM and
KHSRP. Immunoprecipitates were separated by SDS–PAGE and
immunoblotted with antibodies versus the indicated proteins. Note
the absence of signal in IgG immunocomplex. Results illustrated in
Figures 1–6 are representative of three independently performed
experiments.
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using purified recombinant proteins. For this purpose, a
transcript corresponding to the entire intron 3 of the rpL3
gene was used as bait and incubated with the purified re-
combinant proteins His-hnRNP H1 (control), His-NPM
or His-KHSRP and His-rpL7a as a control RNA binding
protein (17). Then, RNA-associated proteins were eluted
and analyzed by western blotting with antibodies against
the endogenous hnRNP H1, NPM, KHSRP and rpL7a.
The presence of signals specific for NPM and KHSRP
indicated that these two proteins are able to recognize
and bind to sequences in the rpL3 intron 3 transcript
(Figure 3B).
KHSRP regulates the alternative splicing of rpL3
pre-mRNA
The identification of a specific interaction of KHSRP with
rpL3 and intron 3 transcript prompted us to investigate a
possible role of KHSRP in the rpL3 gene splicing. To this
aim, we analyzed the effects of the alteration in the expres-
sion levels of KHSRP on the rpL3 RNA splicing pattern.
Increasing amounts of a DNA construct expressing
Flag-KHSRP were transiently transfected in HeLa cells.
Twenty-four hours after transfection, cells were treated
with CHX to stabilize the alternatively spliced isoform
of rpL3 mRNA and lysed. Cells extracts were tested for
the detection of Flag-KHSRP levels by western blotting
with anti-Flag antibodies (Supplementary Figure S2A).
Total RNA from the same cell extract was analyzed by
RT–PCR using specific primers to amplify canonical
(rpL3-c) or alternative (rpL3-a) isoform of rpL3 mRNA.
We observed an increase in the rpL3-a mRNA level
correlated, in a dose-dependent mode, with increasing
amount of KHSRP (Figure 4A). These data indicate
that KHSRP positively affects the selection of the
30-cryptic splicing site within the intron 3 transcript of
rpL3 gene. Thus, we investigated the possibility that
KHSRP could act as a component of rpL3 autoregulatory
loop. We used L3–8 cells, a PC12 Tet-Off cell line stably
transfected with a vector containing the human
rpL3-coding sequence fused to the hemagglutinin (HA)
epitope-coding sequence (14). L3–8 cells were transiently
transfected with the DNA construct expressing
Flag-KHSRP. We chose a dose of Flag-KHSRP that
would result in about a 50% increase of the rpL3 alterna-
tive isoform mRNA. Twenty-four hours after transfec-
tion, we treated cells with CHX and induced the
expression of HA-rpL3 by removing doxycycline from
medium. Cells were then lysed and analyzed for the pro-
duction of Flag-KHSRP and HA-rpL3 by western
blotting using anti-Flag and anti-HA antibodies, respect-
ively (Supplementary Figure S2B). Total RNA was
analyzed by RT–PCR using specific primers to amplify
rpL3-c or rpL3-a mRNAs (Figure 4B). As previously
demonstrated the expression of the HA-rpL3 protein
resulted in an increase of the alternative isoform mRNA
(14). The expression of exogenous KHSRP also caused an
increase in rpL3-a mRNA level. Of interest, the increase in
the rpL3-a mRNA caused by overexpression of KHSRP
was greater after the induction of HA-rpL3 (Figure 4B).
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The effects of KHSRP on rpL3 splicing were also
investigated in condition of mRNA silencing. L3–8 cells
were treated with siRNA specific for KHSRP and, 24 h
after transfection, cells were treated with CHX and
HA-rpL3 production was induced by removing doxycyc-
line from culture medium. Cells were then lysed and
protein extracts were analyzed for the expression of
KHSRP and HA-rpL3 by western blotting using
anti-KHSRP and anti-HA antibodies, respectively. As
shown in Supplementary Figure S2C, the decrease of
KHSRP level was $70% compared to the protein
amount detected in the control lysates. To examine the
effects of the reduced production of KHSRP on the
splicing pattern of rpL3 pre-mRNA, we analyzed total
RNA extracted from the same samples by RT–PCR
using specific primers to amplify rpL3-c and rpL3-a
mRNAs. As expected, in cells overexpressing rpL3, we
observed an increased level of rpL3-a mRNA isoform.
However, in cells, in which KHSRP had been silenced,
rpL3 induced overexpression was less effective in
promoting the production of rpL3-a mRNA isoform
(Figure 4C).
hnRNP H1 role in KHSRP-mediated activity
Since hnRNP H1 (15) and KHSRP have a role in
promoting the alternative splicing of rpL3 gene, we
asked whether a cooperation between these two proteins
would occur and favor the selection of 30-cryptic splicing
site, or whether their functions were redundant. To clarify
this issue, we switched off the expression of the gene
encoding hnRNP H1 by using RNA interference. To
this purpose, siRNAs against hnRNP H1 were transiently
transfected in L3–8 cells. Twenty-four hours after trans-
fection, cells were treated with CHX, induced for
HA-rpL3 production and harvested; RNA and proteins
were extracted. Lysates from cells transfected with
siRNA or untransfected were probed with hnRNP H1
antibodies. As shown in Supplementary Figure S3A, the
residual level of hnRNP H1 was $20% of the protein
detected in the control lysates. To investigate the effects
of the reduced production of hnRNP H1 on the splicing
pattern of rpL3 pre-mRNA, we examined the level of
rpL3 mRNA isoforms using RT–PCR. Under normal
conditions of rpL3 expression, the depletion of hnRNP
H1 resulted in a relevant decrease ($80%) of the alterna-
tive mRNA (rpL3-a) level compared to controls. In con-
ditions of hnRNP H1 removal, rpL3, although
overexpressed, failed to activate the selection of the
30-cryptic splicing site (Figure 5A). These data indicate
clearly that hnRNP H1 plays a crucial role in triggering
the alternative splicing reaction of rpL3 pre-mRNA.
Next, we investigated a possible involvement of hnRNP
H1 in KHSRP-mediated activity. To this aim, we analyzed
the effects of hnRNP H1 depletion and KHSRP
overexpression on rpL3 splicing reaction. L3–8 cells
were transiently co-transfected with siRNA specific for
hnRNP H1 and a DNA construct expressing
Flag-KHSRP. Twenty-four hours after transfection, cells
were treated with CHX, induced for HA-rpL3 expression,
and harvested. hnRNP H1 and KHSRP protein levels
were detected by western blotting (Supplementary Figure
S3B). RNA extracted from the same lysates was analyzed
by RT–PCR. The Figure 5B shows that when hnRNP H1
was depleted, the enforced expression of KHSRP did not
cause an increase of rpL3-a mRNA level, either in normal
conditions of rpL3 expression, or in rpL3 overproduction.
These findings indicate that the ability of KHSRP to in-
fluence the splicing of rpL3 pre-mRNA is mediated by
hnRNP H1.
NPM controls the alternative splicing of rpL3 gene
To study the functional relevance of the interactions of
NPM with rpL3 and intron 3 RNA in the control of the
rpL3 pre-mRNA splicing, we overexpressed NPM in
HeLa cells. Increasing amounts of a DNA construct ex-
pressing HA-NPM were transiently transfected in HeLa
cells. Twenty-four hours after transfection, cells were
treated with CHX and lysed. The expression levels of
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Figure 4. (A) Effects of KHSRP overexpression on rpL3-a mRNA
levels in HeLa cells. Representative RT–PCR analysis of total
RNA from CHX-treated HeLa cells untransfected or transfected
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the recombinant fusion protein were detected by western
blotting using anti-HA antibodies (Supplementary Figure
S4A). The pattern of the spliced rpL3 gene transcript was
monitored by RT–PCR by using specific primers to
amplify rpL3-c and rpL3-a isoforms of rpL3 mRNA. As
shown in Figure 6A, NPM overexpression caused a
dose-dependent decrease of rpL3-a mRNA amounts.
Next, to investigate the role of NPM in the context of
rpL3 autoregolatory loop, we performed experiments of
overexpression and RNAi-mediated silencing of NPM in
L3–8 cell line. Cells were transiently transfected with a
DNA vector expressing HA-NPM. We chose a dose of
HA-NPM that would result in about 50% decrease of
the rpL3-a mRNA isoform. Twenty-four hours after
transfection, cells were treated with CHX and induced
to express HA-rpL3. Cells were then lysed and analyzed
for the production of HA-NPM and HA-rpL3 by western
blotting by using anti-HA antibody (Supplementary
Figure S4B). Total RNA from the same samples was
analyzed by RT–PCR by using specific primers to
amplify rpL3-c and rpL3-a isoforms of rpL3 mRNA.
The overexpression of NPM resulted in a reduction in
the rpL3-a mRNA amount in normal conditions of rpL3
expression, and prevented the increasing of rpL3-a mRNA
level when rpL3 protein was overexpressed (Figure 6B).
To investigate the effects of NPM removal on rpL3 gene
splicing, NPM expression levels were reduced by transfect-
ing L3–8 cells with specific siRNA. Twenty-four hours
after transfection, cells were treated with CHX and
induced to express HA-rpL3. Protein extracts from cells
were tested for the production of HA-NPM and HA-rpL3
by western blotting (Supplementary Figure S4C). Total
RNA was analyzed by RT–PCR by using specific
primers to amplify rpL3-c and rpL3-a mRNA isoforms.
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In physiological conditions of rpL3 expression, following
NPM depletion, the production of rpL3-a mRNA
appeared restored above the control expressing NPM.
Thus, as expected, HA-rpL3 expression upon NPM
silencing caused a significant increase of rpL3-a mRNA
levels (Figure 6C).
DISCUSSION
AS of mRNA is mainly responsible for a variety of gene
products much larger than expected from the number of
genes. It has been estimated that >90% of human genes
are alternatively spliced (18,19). However, a number of
splicing events give rise to mRNA isoforms containing a
PTC that are targeted for decay by NMD. Accumulating
data indicate that association of AS and NMD
(AS-NMD) may result in a quantitative post-
transcriptional regulation of gene expression (7).
In eukaryotes rp expression is regulated by multiple
control mechanisms, mostly at post-transcriptional and
translational level in order to maintain ribosome biosyn-
thesis at the level appropriate to growth conditions and
requirements of the cell (14,15,20,21). However, several
reports indicate that rp, in addition to the role as compo-
nents of the translation machinery, exert a variety of
extraribosomal functions, for which additional, specific
regulatory strategies are required (22,23). Autoregulation
may represent an efficient mechanism to control the level
of a single protein; we have demonstrated previously a role
of AS-NMD in the regulation of the rpL3 gene expression,
promoted by rpL3 protein itself as part of an
autoregulatory negative-feedback loop (14,15).
In an attempt to understand the mechanism of the regu-
latory strategy, we focused our studies on the identifica-
tion of protein partners of the rpL3 protein, and to the
analysis of their contribution to the process. Our previous
results demonstrated that rpL3 protein, within a RNP
complex including the constitutive splicing factor
hnRNP H1, promotes the alternative splicing reaction of
its own gene (15). In most cases, the choice of a splicing
site is made by a dynamic and complex combination of
different splicing regulators; in fact, the function of an
individual splicing factor may be different depending on
interacting partners present in the regulatory network.
The identification of new regulatory proteins and the
mapping of protein–protein interactions within the RNP
complex including rpL3 are crucial steps to understand
the molecular mechanism involved in the selection of the
cryptic 30-splice site within intron 3 transcript of the rpL3
gene. To this aim, we analyzed occurrence of interaction
between rpL3 and putative protein partners previously
identified through a proteomic analysis (15), and the role
of these proteins in the autoregulatory network of rpL3
expression. Our data provide an insight in putative RNP
complexes including hnRNP H1, rpL3 protein,
pre-mRNA of rpL3 gene, and the newly identified
protein factors, NPM and KHSRP, involved in the regu-
lation of rpL3 gene expression via AS-NMD.
NPM is a nucleolar, ubiquitous and multifunctional
phosphoprotein. NPM is involved in multiple biological
functions including the ribosome biogenesis, the control of
cell cycle progression and centrosome duplication. The
cellular activities of NPM are tightly regulated by
multiple factors that seem to be specific for each
function. Post-translational modifications, oligomeriza-
tion and hetero-oligomerization strongly influence the
cellular functions of NPM (24). Emerging evidences
indicate a functional correlation between NPM and
some rp, independent from ribosome biogenesis or its
assembly (25,26). It is known that NPM is involved in
both positive and negative regulation of transcription,
and a possible role of NPM in the splicing process has
been suggested (27). To our knowledge, the present
study demonstrates for the first time a role of NPM as
splicing factor.
KHSRP is a multifunctional RNA-binding protein that
has been mainly implicated in post-transcriptional regula-
tion, mRNA decay and maturation of microRNA precur-
sors (28,29). There are few data supporting an
involvement of KHSRP in the splicing control (30,31).
Analysis of immunoprecipitate of NPM and KHSRP in
HeLa cell extracts showed that NPM and KHSRP
coimmunoprecipitate together with rpL3 and hnRNP
H1, indicating that these proteins associate in vivo,
although the occurrence of multiple complexes including
different combination of protein interactions cannot be
excluded (Figure 1). In addition, in vitro GST pull-down
experiments (Figure 2) demonstrated that NPM and
KHSRP are able to recognize and bind rpL3 and
hnRNPH1, whereas a direct binding between NPM
and KHSRP, or rpL3 and hnRNPH1 has not been
observed.
On the other hand, RNA immunoprecipitation assays
indicated the presence of intron 3 RNA in the
immunoprecipitate of NPM and KHSRP, and RNA
pull-down experiments showed that NPM and KHSRP
are able to contact directly the intron 3 RNA (Figure 3)
as previously shown for hnRNP H1 (15). Taken together,
these data strongly suggest that NPM and KHSRP are
involved in the control of the splicing of rpL3.
Our analysis of the effects of individual expression of
NPM, hnRNP H1 or KHSRP provided an insight also on
the specific role of each protein factor on the rpL3 gene
splicing. In the context of rpL3 autoregulatory circuit,
protein overexpression data indicated that KHSRP repre-
sents a positive regulator of the alternative splicing that
cooperates with rpL3 and hnRNP H1 in the activation of
30-cryptic splice site (Figure 4). However, silencing of
KHSRP caused only $20% decrease of the alternative
mRNA isoform produced when rpL3 is overexpressed,
suggesting that KHSRP is not a crucial player in the
rpL3 autoregulatory loop (Figure 4). Instead, when
hnRNPH1 expression was silenced, rpL3 overexpression
failed to result in the activation of cryptic the 30-splice site
(Figure 5A). These findings together with the observation
that KHSRP, even in excess, was unable to increase the
alternative mRNA isoform in the absence of hnRNP H1
strongly indicate that hnRNP H1 is the key component of
rpL3 autoregulatory loop, while KHSRP might play a role
as an enhancer of hnRNP H1-mediated activation of rpL3
gene alternative splicing (Figure 5B).
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It is known that the RNA binding activity of KHSRP is
mediated by four KH domains. Among these, KH1 and
KH3 domains recognize and bind specifically to a G-rich
target (UGGG and GGGU, respectively) (32). The
analysis of the human intron 3 transcript sequence
showed that G6 motif, an essential element for the
splicing regulatory activity of hnRNP H1, could represent
also a binding site for KH1 or KH3. In addition, the
UGCAUG element, essential to the binding of KHRSP
to src-DCS (Downstream Control Sequence), is also
present in the sequence of intron 3 RNA and it is
located close to the hnRNP H1 binding site G3 and G6
motifs (31). Consequently, it seems plausible to speculate
that KHSRP might interact with these sequences within
intron 3 transcript as well as with hnRNP H1 making
more stable and efficient the association of hnRNP H1
with intron 3 RNA.
Unlike hnRNP H1 and KHSRP, NPM behaves as a
negative regulatory factor of rpL3 gene alternative
splicing (Figure 6). It is possible that the inhibitory
effect of NPM on alternative splicing might be due to a
‘bind and block’ mechanism. In fact, NPM could interact
with sequences within intron 3 pre-mRNA, perhaps in the
vicinity of hnRNP H1 binding sites, and sterically block
the access of hnRNP H1, thus preventing its interaction
with G3 and G6 elements. Since binding of hnRNP H1 to
G-runs site has been demonstrated crucial, the alternative
splicing of rpL3 gene would be negatively affected.
Alternatively, in the light of results demonstrating an
interplay among different protein factors, possibly
assembled in multiple RNP complexes, we propose a
working model, which overcomes the model proposed pre-
viously (15). The model predicts the existence of, at least,
two complexes whose protein composition depends on
rpL3 protein levels. When cell functions require an effi-
cient production of rpL3, the interaction of NPM with
intron 3 pre-mRNA might affect its secondary structure
and mask the binding sites of hnRNP H1. At the same
time, repression of AS might be enforced by a concomi-
tant direct binding of NPM to the positive regulator factor
hnRNP H1 (Figure 7A).
When rpL3 levels exceed cell requirements for rpL3
ribosomal as well as extraribosomal functions, the
protein could interact with NPM; consequently, NPM
would be released from the RNP complex to which rpL3
could be associated by interacting with KHSRP. The
removal of NPM, and the rearrangement of the inter-
actions within the RNP complex, could make available
the enhancer unit G3+G6 within intron 3 transcript
and, at the same time, the presence of rpL3 in the re-
modeled complex could induce conformational changes
that favor the interaction of hnRNP H1 with G3+G6.
Finally, such complex could promote the activation of
the alternative mode of splicing reaction (Figure 7B).
At the present, the challenge is to determine the hier-
archy of interactions leading to the assembly of RNP
complexes, and the dynamic nature of protein–protein
interactions causing the remodeling of complexes respon-
sible for the modulation of the splicing of the rpL3 gene.
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Figure S1. NPM or KHSRP were specifically immunoprecipitated from HeLa cells 
extracts with antibodies against the endogenous NPM and KHSRP. 
Immunoprecipitates and supernatants were separated by SDS-PAGE and 
immunoblotted for NPM and KHSRP.  
 
Figure S2. (A) Effects of KHSRP overexpression on rpL3-a mRNA levels in HeLa 
cells. Protein samples from CHX-treated HeLa cells untransfected or transfected with 
increasing amount of Flag-KHSRP were analyzed by western blotting (WB) with an 
antibody directed against the Flag tag. (B) Effects of KHSRP overexpression on rpL3-
a mRNA levels in L3-8 cells. Protein samples from CHX-treated L3-8 cells 
untransfected or transfected with Flag-KHSRP, non induced (NI) or induced (I) for 
HA-rpL3 expression were analyzed by western blotting (WB) with antibodies 
directed against the HA and the Flag tags. (C) Effects of RNAi-mediated depletion of 
KHSRP on rpL3-a mRNA levels in L3-8 cells. Protein samples from CHX-treated 
L3-8 cells untransfected or transfected with KHSRP-siRNA, non induced (NI) or 
induced (I) for HA-rpL3 expression were analyzed by western blotting (WB) with 
antibody specific for endogenous KHSRP and HA tag. 
The levels of proteins were quantified by PhosphorImager (Bio-Rad) and normalized 
to tubulin levels. 
 
Figure S3. (A) Effects of RNAi-mediated depletion of hnRNP H1 on rpL3-a mRNA 
levels in L3-8 cells. Protein samples from CHX-treated L3-8 cells, untransfected or 
transfected with hnRNP H1-siRNA, non induced (NI) or induced (I) for HA-rpL3 
expression were analyzed by western blotting (WB) with antibody specific for the 
endogenous hnRNP H1 and HA tag. (B) Effects of RNAi-mediated depletion of 
hnRNP H1 and KHSRP overexpression on rpL3-a mRNA levels in L3-8 cells. Protein 
samples from CHX-treated L3-8 cells untransfected or cotransfected with hnRNP H1-
siRNA and Flag-KHSRP, non induced (NI) or induced (I) for HA-rpL3 expression 
were analyzed by western blotting (WB) with antibody specific for endogenous 
hnRNP H1 and with antibody directed against the HA and Flag tags. 
The levels of proteins were quantified by PhosphorImager (Bio-Rad) and normalized 
to tubulin levels. 
 
Figure S4. (A) Effects of NPM overexpression on rpL3-a mRNA levels in HeLa 
cells. Protein samples from CHX-treated HeLa cells untransfected or transfected with 
increasing amount of HA-NPM were analyzed by western blotting (WB) with an 
antibody directed against the HA tag. (B) Effects of overexpression of NPM on rpL3-
a mRNA levels in L3-8 cells. Protein samples from CHX-treated L3-8 cells 
untransfected or transfected with HA-NPM, non induced (NI) or induced (I) for HA-
rpL3 expression were analyzed by western blotting (WB) with antibody directed 
against the HA tag. (C) Effects of silencing of NPM on rpL3-a mRNA levels in L3-8 
cells. Protein samples from CHX-treated L3-8 cells untransfected or transfected with 
siRNA against NPM, non induced (NI) or induced (I) for HA-rpL3 expression were 
analyzed by western blotting (WB) with antibody directed against the HA tag and 
NPM.  
The levels of proteins were quantified by PhosphorImager (Bio-Rad) and normalized 
to tubulin levels. 
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Introduction
p21 (also known as p21waf1/cip1), a main inhibitor of cyclin-
dependent kinases (CDKs), is a negative regulator of cell cycle 
progression; various regulatory mechanisms contribute to finely 
coordinate multiple biological functions of p21 and determine its 
intracellular levels. They include transcriptional regulation, epi-
genetic silencing, mRNA translation and stability and ubiquitin-
dependent as well as ubiquitin-independent degradation of the 
protein.1,2
In addition to growth-inhibiting activities, p21 can induce 
or repress p53-dependent or p53-independent apoptosis depend-
ing on the cellular system or the nature of the stress.3-5 In fact, 
p21 gene overexpression in human laryngeal squamous carci-
noma cells lacking p53 protein expression enhances apoptosis in 
cisplatin-treated cells, whereas it attenuates apoptotic signals in 
methotrexate-treated cells.6
A variety of transcription factors can modulate p21 in addi-
tion to p53.7 The p21 promoter consists of proximal and distal 
regulatory elements. The majority of p21 gene regulatory proteins 
interact with the proximal region of p21 promoter that includes 
six GC-rich binding sites recognized by Sp1, Sp3 and Kruppel-
like transcription factors.8,9 Numerous evidences support the 
essential role of Sp1 in the upregulation of p21 gene by several 
protein factors such as c-Myc10 or drugs, such as Mithramycin A, 
Sulforaphane and 5-FU.11,12
It is now largely accepted that ribosomal proteins may be implicated in a variety of biological functions besides that of 
components of the translation machinery. Many evidences show that a subset of ribosomal proteins are involved in the 
regulation of the cell cycle and apoptosis through modulation of p53 activity. In addition, p53-independent mechanisms of 
cell cycle arrest in response to alterations of ribosomal proteins availability have been described. Here, we identify human 
rpL3 as a new regulator of cell cycle and apoptosis through positive regulation of p21 expression in a p53-independent 
system. We demonstrate that the rpL3-mediated p21 upregulation requires the speci!c interaction between rpL3 and 
Sp1. Furthermore, in our experimental system, p21 overexpression leads to a dual outcome, activating the G1/S arrest of 
the cell cycle or the apoptotic pathway through mitochondria, depending on its intracellular levels. It is noteworthy that 
depletion of p21 abrogates both e"ects. Taken together, our !ndings unravel a novel extraribosomal function of rpL3 and 
reinforce the proapoptotic role of p21 in addition to its widely reported ability as an inhibitor of cell proliferation.
Human rpL3 induces G1/S arrest or apoptosis  
by modulating p21waf1/cip1 levels  
in a p53-independent manner
Annapina Russo,1,2 Davide Esposito,1 Morena Catillo,1 Concetta Pietropaolo,1 Elvira Crescenzi3 and Giulia Russo1,*
1Dipartimento di Biochimica e Biotecnologie Mediche; Università Federico II; Napoli, Italy; 2CEINGE Biotecnologie Avanzate S.C.a.r.l.; Napoli, Italy;  
3Istituto di Endocrinologia e Oncologia Sperimentale; CNR; Napoli, Italy 
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In eukaryotes, many data indicate that r-proteins exert a vari-
ety of extra-ribosomal functions. Alteration in the expression of 
r-proteins and protein factors involved in the ribosome biogen-
esis correlate with tumorigenesis, since many of these proteins 
are overexpressed in solid tumors and leukemia cells.13,14 On the 
other hand, some data suggest that several r-proteins might have 
a role as tumor suppressors, as described in zebrafish.15 Recently, 
an increasing number of r-proteins have been proposed as addi-
tional important components of the tumor suppressor p53’s auto-
regulatory feedback loop, activating p53 and triggering cell cycle 
arrest and apoptosis.16 In fact, either drug treatment or enforced 
expression of rpL11, rpL5, rpL23 causes p53-dependent cell-
cycle arrest through HDM2 (human double minute 2) inter-
action.17-19 In addition to r-proteins, several nucleolar proteins 
such as NPM (Nucleophosmin, also known as B23, numatrin or 
NO38) and Nucleostemin are able to modulate p53 activity.20,21 
Furthermore, emerging evidences indicate a functional cor-
relation between NPM and some r-proteins, independent from 
ribosome biogenesis. It has been shown that rpL23 regulates 
NPM and Miz1-dependent p21 gene promoter transactivation 
by sequestering NPM into the nucleolus.22 We have studied in 
recent years post-transcriptional regulatory strategies of mamma-
lian r-proteins,23 and we demonstrated that human r-protein L3 
(rpL3) autoregulates, in a complex with the transacting factors 
hnRNP H1, NPM and KHSRP, its own expression through the 
association of alternative splicing and nonsense-mediated mRNA 
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Next, in order to evaluate whether rpL3 was able to interact 
directly with p21 proximal promoter region, an EMSA experi-
ment was performed using purified recombinant GST-tagged 
rpL3 and GST as control. No mobility shift was observed when 
recombinant GST-rpL3 was challenged with the probe, sug-
gesting that the binding of rpL3 to the p21 gene promoter is 
indirect, and it may require additional protein factors (data not 
shown).
NPM modulates rpL3-dependent p21 gene promoter trans-
activation. The absence of a direct binding between rpL3 and 
p21 promoter prompted us to search for rpL3-interacting regula-
tory proteins involved in the rpL3-mediated regulation of p21 
transcription. We have previously reported a direct protein-pro-
tein interaction between rpL3 and NPM and demonstrated that 
this interaction is functional to the regulation of the rpL3 gene 
alternative splicing.24
Here, we explored the possibility that the rpL3-NPM complex 
was involved in the transactivation of the p21 gene transcription.
To this purpose, we performed analogous ChIp experiments 
by using anti-rpL3, anti-NPM and anti-IgG as control. As shown 
in Figure 3A, the presence of NPM and rpL3 proteins (WB), and 
a signal for p21 gene promoter (qPCR) in the reciprocally DNA-
immunoprecipitated complexes, absent in the control obtained 
with anti-IgG antibodies, were consistent with the presence of 
rpL3 and NPM on the p21 gene promoter.
To investigate whether the interaction between rpL3 and 
NPM on p21 promoter affects its activity, a reporter luciferase 
assay was performed by altering intracellular levels of NPM in 
conditions of HA-rpL3 overexpression. The results demonstrated 
that either in rpL3 physiological conditions or rpL3 overexpres-
sion, the enforced expression of NPM did not affect the activity 
of p21 gene promoter (Fig. 3B). Whereas, in physiological condi-
tions of rpL3 expression, the NPM silencing was associated with 
the inhibition of p21 transcriptional activity as indicated by a 
significant decrease (about 40%) in p21 gene promoter activity 
(Fig. 3C). Of interest, in rpL3 overexpression conditions, NPM 
silencing resulted in a decrease of rpL3-dependent transactiva-
tion of p21 gene promoter. These data suggest a positive role of 
NPM in rpL3-mediated activity on p21 gene promoter.
rpL3-dependent p21 gene promoter transactivation requires 
Sp1. In the attempt to identify other proteins involved in the 
rpL3-mediated activation of p21 transcription, we focused our 
study on the possible role of Sp1, a protein factor that regulates 
p21 transcription.8 We first determined whether Sp1 was present 
in the rpL3-p21 gene promoter immunocomplex. To this pur-
pose, a ChIp experiment in condition of mythramycin A (MTM) 
decay (AS-NMD).24,25 In this paper, we demonstrate that rpL3 is 
a positive regulator of p21 expression. We show that rpL3 is able 
to modulate the protein amounts of p21 through a novel pathway 
independent from p53 involving Sp1 and NPM. Furthermore, 
we observed that rpL3-mediated p21 upregulation results in cell 
cycle arrest or apoptosis depending on the intracellular levels of 
p21 protein.
Results
rpL3 upregulates p21 expression at transcriptional levels inde-
pendently from p53. In order to investigate whether rpL3 could 
control p21 expression in a cell environment devoid of p53, we 
analyzed p21 mRNA and protein levels by western blotting and 
semiquantitative RT-PCR upon rpL3 overexpression in Calu-6 
cells lacking p53 protein expression.23 The enforced expression 
of the HA-rpL3 protein resulted in a dose-dependent increase of 
p21 protein and mRNA (Fig. 1A and B).
To investigate the possibility that p21 upregulation is due 
to the ability of rpL3 to control the activity of p21 promoter, 
we performed a reporter luciferase assay in conditions of rpL3 
overexpression.
For the specificity of the assay, a plasmid expressing rpL7a-His 
(pL7a-His), an arbitrary ribosomal protein, was used as control.26 
As shown in Figure 1C, the enforced expression of rpL3, in con-
trast to rpL7a, is associated to the upregulation of p21 gene pro-
moter transactivation in a dose-dependent manner.
In addition, we performed analogous experiments by using 
pCMV, a plasmid containing the CMV promoter fused to lucif-
erase DNA, as a further control (Fig. 1D). The results showed 
that rpL3, as rpL7a, failed to enhance reporter gene expression 
driven by CMV promoter.
rpL3 binds the p21 gene promoter. We investigated whether 
rpL3 was able to interact with p21 gene promoter. To this aim, 
Calu-6 cells were collected and subjected to ChIP by using anti-
rpL3 and anti-IgG as specificity control.
The presence of rpL3 was investigated by western blotting in 
the DNA-immunoprecipitated complexes (Fig. 2). Quantitative 
PCR assay on the samples was performed by using primers spe-
cific for proximal region of p21 promoter (-194–+88),27 which is 
the region interacting with the majority of p21 regulatory pro-
teins, and primers for control loci.
The presence of a specific signal for p21 promoter in the 
DNA-rpL3 immunocomplex, absent in the control challenged 
with anti-IgG antibodies, indicated that rpL3 is able to bind p21 
promoter (Fig. 2).
Table 1. Primers used in PCR reactions
Primers Forward (5'-3') Reverse (5'-3')
NPM cDNA ATG GAA GAT TCG ATG GAC TTA AAG AGA CTT CCT CCA
Sp1 cDNA ATG GAT GAA ATG ACA GCT TCA GAA GCC ATT GCC ACT
p21 cDNA ATG TCA GAA CCG GCT GGG TTA GGG CTT CCT CTT GGA
β-actin GGC ACC ACC TTC TAC A CAG GAG GAC AAT GAT
p21 promoter -194/+88 ACC GGC TGG CCT GCT GGA ACT TCT GCC GCC GCT CTC TCA CCT
p21 3'-UTR +3455/+3771 ATG TTA GGC AAG TTA CTT AAC TTA CTC TTG GTA ACT TCA CAC CAA GTT
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and a signal for p21 gene promoter (qPCR), in the reciprocally 
DNA-immunoprecipitated complexes, not detected in the con-
trol obtained with anti-IgG antibodies, in absence of MTM, 
treatment was performed. MTM is a specific Sp1 inhibitor that 
is able to displace Sp1 from its binding sites in numerous genes.11 
The Figure 4 shows the presence of Sp1 and rpL3 proteins (WB), 
Figure 1. Role of rpL3 in the regulation of p21 expression. (A) Protein samples from Calu-6 cells untransfected or transiently transfected with increas-
ing amounts (0, 0.5, 1, 2 μg) of a plasmid expressing rpL3 fused to HA tag (pHA-rpL3) were analyzed by WB assay, with antibodies directed against the 
HA tag and p21, 24 h after transfection. Loading in the gel lanes was controlled by detection of α-tubulin protein. (B) Representative RT-PCR analysis 
of total RNA from the same samples. β-actin was used as a control of RNA loading. Quanti!cation of p21 protein and mRNA levels by PhosphorImager 
(Bio-Rad) is shown. (C) Protein extracts from Calu-6 cells transiently transfected with the full-length p21 promoter luciferase reporter plasmid (pWWP) 
alone and cotransfected with pWWP and increasing amounts of pHA-rpL3 or pL7a-His (0, 0.5, 1, 2 and 4 μg) were analyzed by WB assay with antibod-
ies directed against the HA and His tags, 24 h after transfection. Loading in the gel lanes was controlled by detection of α-tubulin protein. Analysis 
of the relative luciferase activity, normalized against Renilla Luciferase (pRL) activity, in the same samples. (D) Protein extracts from Calu-6 cells 
transiently transfected with CMV-Luc plasmid alone, or cotransfected with pCMV-Luc and 2 μg of pHA-rpL3 or pL7a-His, were analyzed by WB assay 
with antibodies directed against the HA and His tags. Loading in the gel lanes was controlled by detection of α-tubulin protein. The relative luciferase 
activity, normalized against Renilla Luciferase (pRL) activity, in the same samples was detected. Results illustrated in Figures 1–9 are representative of 
three independently performed experiments.
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plasmids in which two or four Sp1-binding sites were simulta-
neously deleted (pWP101 and pWPdel-SmaI)29 in presence or 
absence of pHA-rpL3 (Fig. 5B). As shown in Figure 5B, upon 
the overexpression of rpL3, deletion of Sp1-binding sites 1 and 2 
(pWP101) led to an increase in the luciferase activity comparable 
to that obtained when all the six Sp1 binding motifs were pres-
ent (pWP124), whereas additional deletion of Sp1-binding sites 3 
and 4 (pWPdel-SmaI) abrogated completely rpL3’s effect on p21 
gene promoter transactivation. These data suggest that the region 
spanning from -60–-101 upstream from the transcription start 
site, including Sp1-binding sites 3 and 4, corresponds to rpL3-
responsive element, and it is involved in rpL3-mediated activa-
tion of p21 gene promoter.
rpL3 overexpression induces cell cycle arrest or apoptosis in 
Calu-6 cells. In order to investigate the effect of rpL3-mediated 
upregulation of p21 transcription on cell proliferation, we per-
formed 5-Bromodeoxyuridine (BrdU) incorporation to monitor 
DNA synthesis during cell division and propidium iodide (PI) 
staining to analyze DNA content of Calu-6 cells transiently 
transfected with 1 μg or 2 μg of pHA-rpL3. As expected, rpL3 
overexpression induced an increase of p21 expression in a dose-
dependent manner. Figure 6 shows that BrdU incorporation 
in cells transfected with 1 μg of pHA-rpL3 was significantly 
decreased vs. that observed in control (about 0.7% vs. 25%, 
respectively). This indicated that the enforced expression of rpL3 
produced a strong reduction in the percentage of cells in S-phase 
of the cell cycle. Analysis of cell cycle using the counterstaining 
with PI indicated that the observed decrease of cells in S-phase 
was associated with an increase of cell population in the G1-phase 
of the cell cycle (about 80% vs. control 50%). Surprisingly, in the 
presence of higher rpL3 levels (2 μg of pHA-rpL3), we observed 
only a mild effect on the cell cycle, but rather the presence of a 
significant sub-G1 population, indicative of apoptosis (about 21% 
vs. control 2%).
Intracellular levels of rpL3 affect the choice between G1/S 
arrest or mitochondrial apoptosis in Calu-6 cells. To gain fur-
ther insight into the mechanism by which rpL3 causes cell cycle 
arrest and apoptosis, we proceeded to perform a time-course 
analysis of the nuclei DNA content of Calu-6 cells transiently 
transfected with 1 μg or 2 μg of pHA-rpL3 by flow cytometry 
(Fig. 7).
In cells transfected with 2 μg of pHA-rpL3, an increase in 
sub-G1 cell population vs. control was observed at all time points, 
although the strongest effect was obtained after 48 h. At this time 
point, the percentage of cells transfected with 2 μg of pHA-rpL3 
in the sub-G1 phase of the cell cycle increased approximately 
7-fold as compared with control (about 36% vs. 5%, respec-
tively). This effect was not observed with 1 μg of pHA-rpL3. 
Transfection of cells with this amount of pHA-rpL3 did not 
induce apoptosis even 72 h after transfection. Furthermore, we 
observed a G1/S arrest at 24 and 48 h (as already shown), and 
more interestingly, at 72 h, the dividing ability of Calu-6 cells 
transfected with 1 μg pHA-rpL3 was restored, as evidenced by 
the presence of a G2/M peak (Fig. 7).
These results suggest that rpL3 may induce G1/S arrest or 
apoptosis depending on its concentration inside the cells.
indicating that a specific association between Sp1 and rpL3 
occurs on the p21 gene promoter.
Of interest, the presence of MTM prevents the binding of 
both rpL3 and Sp1 on the p21 gene promoter, indicating that 
rpL3 is able to bind p21 gene promoter only in the presence of 
Sp1.
In order to study the function of Sp1 in rpL3-dependent 
transactivation of p21 gene promoter, a reporter luciferase assay 
was performed in conditions of rpL3 and Sp1 overexpression, 
with or without MTM. Figure 5A shows that in absence of 
MTM, rpL3 or Sp1 overexpression increased the activity of p21 
gene promoter, as previously observed (see sub-section “rpL3 
upregulates p21 expression at transcriptional level indepen-
dently from p53” in this paper and ref. 28). In addition, rpL3 
and Sp1 had a synergistic effect on the transactivation of p21 
gene promoter. Interestingly, the ability of both rpL3 and Sp1 
to activate the transcription of luciferase was strongly reduced 
in the presence of MTM. These data suggest that the ability of 
rpL3 to activate p21 transcription requires the presence of Sp1 
on the promoter.
Sp1-binding boxes 3 and 4 are involved in rpL3-dependent 
transactivation of p21 gene promoter. The proximal region of 
the human p21 promoter carries six GC-rich Sp1-binding sites 
(numbered 1–6 in plasmid pWP124, Fig. 5B). To determine 
which of Sp1-binding elements mediate rpL3 responsiveness, 
Calu-6 cells were transiently transfected with pW124 or mutant 
Figure 2. Analysis of the interaction between rpL3 and p21 gene pro-
moter. Protein samples from DNA-rpL3 or DNA-IgG immunocomplexes 
were analyzed through WB assay with antibody against rpL3. Note the 
absence of signal in DNA-IgG immunocomplex. The same DNA-immu-
noprecipitates were subjected to quantitative PCR (qPCR) with primers 
speci!c for the proximal region of p21 gene promoter or control loci.
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Figure 3. Role of NPM in the rpL3-mediated p21 gene transcriptional transactivation. (A) Analysis of the interaction between NPM and rpL3 on p21 
gene promoter. Protein samples from DNA-rpL3, DNA-NPM or DNA-IgG immunocomplexes were analyzed through WB assay with antibodies against 
the indicated proteins. Note the absence of signal in IgG immunocomplex. The same DNA-immunoprecipitates were subjected to quantitative PCR 
(qPCR) with primers speci!c for the proximal region of p21 gene promoter or control loci. (B) E"ect of NPM overexpression on rpL3-mediated p21 
gene promoter activity. Protein extracts from Calu-6 cells transiently transfected with pWWP alone or cotrasfected with pWWP, and the plasmids ex-
pressing the recombinant Flag-NPM (pFlag-NPM), with or without pHA-rpL3, were analyzed by WB assay with antibodies directed against the HA and 
Flag tags. Loading in the gel lanes was controlled by detection of α-tubulin protein. The relative luciferase activity, normalized against Renilla Lucif-
erase (pRL) activity, in the same samples was detected. (C) E"ects of RNAi-mediated depletion of NPM on rpL3-mediated p21 gene promoter activity. 
Protein extracts from Calu-6 cells transiently transfected with pWWP alone or cotrasfected with pWWP and siRNA directed against endogenous NPM 
mRNA (siRNA-NPM) in presence or absence of pHA-rpL3 were analyzed by WB assay with antibodies directed against the HA tag and NPM. Loading in 
the gel lanes was controlled by detection of α-tubulin protein. The relative luciferase activity, normalized against Renilla Luciferase (pRL) activity, in 
the same samples was detected.
To further study the apoptotic effect of rpL3, we analyzed 
PARP protein cleavage by western blotting analysis and reduc-
tion of mitochondrial inner membrane potential (ΔΨm) by 
tetramethyl-rhodamine ethyl ester (TMRE) staining, hall-
marks of mitochondrial apoptosis,30,31 in Calu-6 cells trans-
fected with 2 μg of pHA-rpL3. As expected, in these cells, 
western blot for PARP revealed an increased amount of cleaved 
PARP (Fig. 8A). Furthermore, Figure 8B shows that the per-
centage of Calu-6 cells with a physiological ΔΨm decreased 
from 88% to 58% (control cells vs. 2 μg of pHA-rpL3 trans-
fected cells). Overall, these results indicate that higher 
levels of rpL3 protein obtained with 2 μg of pHA-rpL3 acti-
vate apoptosis through mitochondrial pathway in Calu-6 
cells.
Cell cycle arrest and apoptosis upon rpL3 overexpression 
are p21-dependent. To verify that rpL3-induced cell cycle arrest 
or apoptosis in Calu-6 cells occurs through a specific pathway 
involving p21, we examined the effects of rpL3 overexpression on 
cell proliferation and cell death after p21 silencing.
We performed analysis of the nuclei DNA content of Calu-6 
cells and p21-depleted Calu-6 (p21ΔCalu-6) cells transiently 
transfected with 1 μg or 2 μg of pHA-rpL3 by flow cytometry. 
Figure 9A (lower panels) shows that rpL3 was unable to induce 
cell cycle arrest in condition of p21 depletion. In addition, as 
shown in Figure 9B (lower panels), the higher dosage of rpL3 
failed to mediate the induction of apoptosis in p21-depleted cells, 
thus demonstrating that the dual effect of rpL3 on cell cycle arrest 
or apoptosis is dependent from p21. All these results indicate that 
©
20
13
 L
an
de
s 
B
io
sc
ie
nc
e.
 D
o 
no
t d
is
tri
bu
te
.
www.landesbioscience.com Cell Cycle 81
Figure 4. Analysis of the interaction between rpL3 and Sp1 on p21 gene promoter. Protein samples from DNA-rpL3, DNA-Sp1 or DNA-IgG immuno-
complexes from Calu-6 cells untreated or treated with 200 nM of mythramycin A (MTM) for 16 h were analyzed through WB assay with antibodies 
against rpL3 or Sp1. Note the absence of signal in DNA-IgG immunocomplex. The same DNA immunoprecipitates were subjected to quantitative PCR 
(qPCR) with primers speci!c for the proximal region of p21 gene promoter or control loci.
Figure 5. Role of Sp1 in the rpL3-mediated p21 gene transcriptional transactivation. (A) Protein extracts from Calu-6 cells untreated or treated 
with 200 nM of mythramycin A (MTM) and transiently transfected with pWWP alone, or in the presence of pHA-rpL3 or the plasmid expressing the 
recombinant Sp1-His (pSp1-His) or pHA-rpL3 and pSp1-His were analyzed by WB assay with antibodies directed against the HA and His tags, 24 h after 
transfection. Loading in the gel lanes was controlled by detection of α-tubulin protein. The relative luciferase activity, normalized against Renilla 
Luciferase (pRL) activity, in the same samples was detected. (B) Analysis of p21 promoter regions involved in rpL3-mediated p21 gene transcriptional 
activation. On the left, schematic representation of the deletion constructs of the p21 gene promoter used in the luciferase transfection assay. Calu-6 
cells were transiently transfected with the pWP124, pWP101 or pWPdel-SmaI in presence or absence of pHA-rpL3. Proteins were analyzed by WB assay 
with antibody directed against the HA tag 24 h after transfection. Loading in the gel lanes was controlled by detection of α-tubulin protein. Analysis of 
the relative luciferase activity, normalized against Renilla Luciferase (pRL) activity, in the same samples is shown.
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response pathway in the coregulation of these events has been 
widely demonstrated.36,37 Alterations in processes such as rRNAs 
synthesis, rRNAs modification as well as r-proteins imbalance 
produce alterations in ribosome biogenesis and result in nucleolar 
stress. In response to this event, several r-proteins translocate to 
the nucleoplasm and bind to Mdm2, thus promoting p53 stabi-
lization and subsequent p53-mediated cell cycle arrest or apop-
tosis.38 Several p53-independent pathways that require nucleolar 
proteins, such as ARF, NPM or free r-proteins, have also been 
well-studied.39,40
Data reported in this paper allow us to define a new extraribo-
somal function for human rpL3 in addition to its role in the reg-
ulation of the alternative splicing of its own gene.23 Specifically, 
we demonstrate that rpL3 is able to induce cell cycle arrest or 
rpL3 is able to induce cell cycle arrest or activate the intrinsic 
apoptotic pathway in Calu-6 cells by regulating the intracellular 
amounts of p21.
Discussion
In eukaryotes, ribosome biogenesis is a complex process that 
requires a number of coordinated events prior to nuclear export 
of the mature subunits to the cytoplasm.32-34 Recent studies have 
shed new light on the mechanisms underlying the regulation of 
these events and revealed new connections between ribosome 
biogenesis and cell cycle.35 The signaling pathways able to con-
nect these two processes have long been relatively unknown; 
however, more recently, the role of r-proteins-Mdm2-p53 stress 
Figure 6. E"ects of rpL3-mediated upregulation of p21 gene expression on the cell cycle. (A) Protein samples from Calu-6 cells transfected with 2 μg 
of pcDNAHAV3 (empty vector), 1 μg or 2 μg of pHA-rpL3 were analyzed by WB assay with antibodies directed against the HA tag and p21. Loading in 
the gel lanes was controlled by detection of α-tubulin protein. (B) The same samples were stained with FITC conjugated anti-5-bromodeoxyuridine 
antibody and counterstained with propidium iodide and analyzed for DNA synthesis and for DNA content by $ow cytometry 48 h after transfection. 
On the bottom, the percentage of cells in di"erent phases of cell cycle is shown.
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It is well-known that p21 proximal promoter contains six Sp1 
binding sites, and that Sp1 is able to transcriptionally regulate the 
activity of different genes including those involved in the regula-
tion of cell cycle.8 Specifically, Sp factors have been proposed to 
be essential for transactivation of the p21 promoter by members 
of the p53 family proteins.41 Here, we demonstrate that rpL3 
associates in vivo with Sp1 on the p21 proximal promoter only in 
absence of MTM. Although treatment with MTM did not pre-
vent the formation of a complex between rpL3 and Sp1 into the 
cells, it hindered its recruitment on p21 promoter (Fig. 4). Data 
from rpL3 and Sp1 overexpression in Calu-6 cells in absence of 
MTM indicated that expression of Sp1, in combination with 
rpL3, strongly increased rpL3-mediated p21 transactivation; 
these findings, together with the observation that rpL3, even in 
excess, was unable to transactivate p21 promoter in presence of 
MTM, strongly indicated that the binding of Sp1 to the proximal 
apoptosis in Calu-6 cells by positively modulating the activity 
of p21 promoter in a p53-independent pathway. To our knowl-
edge, the present study demonstrates for the first time a direct 
role of an r-protein, specifically rpL3, in the regulation of p21 
transcription.
In an attempt to understand the mechanism of the rpL3-medi-
ated upregulation of p21 expression, we focused our studies on the 
identification of protein partners of rpL3 protein involved in this 
activity. It is known that NPM is able to indirectly bind to p21 
proximal promoter and activate its transcription.22 Furthermore, 
our previous results demonstrated that NPM is able to interact 
directly with rpL3, and that this interaction is functional to 
the regulation of the rpL3 protein levels inside the cells.24 Data 
reported in this paper clearly demonstrate that NPM represents a 
positive regulator of rpL3-mediated transactivation of p21 gene, 
although it is not a crucial player in this event (Fig. 3).
Figure 7. E"ects of rpL3-mediated upregulation of p21 gene expression on the cell viability. Calu-6 cells transfected with 2 μg of pcDNAHAV3 (empty 
vector) or 1 μg and 2 μg of pHA-rpL3 were analyzed for DNA content by propidium iodide staining 24 h, 48 h and 72 h after transfection. On the bot-
tom, a quanti!cation of percentage of cells in sub-G1 phase is shown.
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Data reported in this paper indicate that rpL3 in a complex 
with Sp1 and NPM is able to positively transactivate p21 pro-
moter. The p21 overexpression induced by this complex could 
trigger two distinct pathways: cell cycle arrest or mitochondrial 
apoptosis in a context devoid of p53. Although the molecular 
details underlining these mechanisms remain to be clarified, 
we speculate that the intracellular levels of p21 achieved upon 
modulation of the rpL3 amounts are determinant of cell fate. In 
the lights of these observations, our working model predicts that 
the intracellular levels of rpL3 could be crucial in regulating the 
hierarchy of interactions of p21 with multiple factors, leading to 
the assembly of specific protein complexes, which could trigger 
two distinct effects: cell cycle arrest or apoptosis.
At the present, the challenge is to identify the p21 molecular 
partners involved in the cellular response to rpL3 overexpres-
sion. This will help to elucidate the role of ribosomal proteins in 
the control of cell cycle and cell death through p21-dependent 
molecular pathways.
Materials and Methods
Cell cultures, transfections and drug treatment. Human cell line 
Calu-623 was cultured in Dulbecco’s modified Eagle’s medium 
(DMEM) with glutamax (Invitrogen) supplemented with 10% 
fetal bovine serum (FBS), 0.1 mM non-essential amino acids 
(Euroclone), 2 mM L-glutamine and penicillin-streptomycin 
50 U/ml.
p21 promoter region is essential for the 
rpL3-mediated transactivation of p21 
promoter. Thus, we propose that Sp1 
is a key component of rpL3-mediated 
p21 transactivation; in fact, Sp1 bind-
ing to GC boxes 3 and 4 is a prereq-
uisite for rpL3 recruitment on p21 
proximal promoter (Fig. 5).
In the light of these results, we 
propose a working model in which 
overexpression of rpL3, which may 
mimic situations of alteration in ribo-
some biogenesis, leads to a formation 
of a multiprotein complex contain-
ing at least rpL3, Sp1 and NPM on 
the proximal region of p21 promoter 
with consequent upregulation of p21 
expression. This upregulation leads to 
a dual effect; arresting the cell cycle 
progression at G1/S phase or promot-
ing apoptosis in dependence of rpL3 
and p21 protein levels into the cells 
(Fig. 6). To better understand the 
dynamics of these events, we per-
formed a time-dependent analysis of 
the DNA content in Calu-6 cells trans-
fected with different amounts of pHA-
rpL3. Interestingly, we observed that 
1 μg of pHA-rpL3 induced a revers-
ible G1/S arrest of the cell cycle. In fact, Calu-6 cells restored 
their capability to progress through the G1/S transition at 72 h 
after transfection. Instead, transfection with 2 μg of pHA-rpL3 
triggered mitochondrial apoptosis even at 24 h after transfection 
(Figs. 7 and 8). Moreover, we show that p21 is essential for rpL3-
induced cell cycle arrest or mitochondrial apoptosis, since stable 
depletion of p21 in Calu-6 cells completely abolished both events 
(Fig. 9). Taken together, these data demonstrate that rpL3 plays 
an important role in the activation, through modulation of p21 
levels, of two independent pathways; i.e., reversible arrest of cell 
cycle or mitochondrial apoptosis.
These data are in complete agreement with recent evidences 
demonstrating a much more complex scenario than had been 
expected regarding p21’s role in the regulation of cell cycle. In 
particular, p21 has proved to exert also a proapoptotic function 
under certain conditions in specific systems beyond the well-
known role in growth inhibition.42 Notably, in most of these 
cases, the cellular systems used express a non-functional p53 
isoform. The mechanism by which p21 may promote apoptosis 
is poorly understood, and different working models have been 
proposed. However, the common assumption is that the cellu-
lar activities of p21 are tightly regulated by multiple factors that 
seem to be specific for each function in different systems. For 
example, the interaction of p21 with PCNA is implicated in 
sodium butyrate-induced apoptosis,43 other studies indicate that 
the modulation of proapoptotic or antiapoptotic genes is respon-
sible for p21-induced apoptosis.44,45
Figure 8. Characterization of rpL3-mediated apoptosis in Calu-6 cells. (A) Calu-6 cells transfected with 
2 μg of pcDNAHAV3 (empty vector) or pHA-rpL3 were analyzed by WB assay with antibodies directed 
against PARP, the HA tag and p21, 48 h after transfection. Loading in the gel lanes was controlled by 
detection of α-tubulin protein. (B) The same samples were analyzed for mitochondrial membrane 
potential by tetramethyl-rhodamine ethyl ester (TMRE) staining, and $uorescence was measured by 
$ow cytometry 48 h after transfection.
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Transfection efficiency was assessed 
by cotransfecting a GFP-expressing 
vector and normalizing RNA levels 
against GFP mRNA levels (data not 
shown).
Calu-6 cells (2.5 × 106 cells, 60 mm-
well plate) were treated with 200 nM 
Mithramycin A (Sigma-Aldrich) for 
16 h before transfections or chromatin 
immunoprecipitation.
Plasmids and production of 
recombinant proteins. The cDNAs 
of NPM and Sp1 were obtained by 
RT-PCR from Calu-6 cells using spe-
cific primers (Table 1) and cloned into 
a version of the eukaryotic expression 
vector pcDNA3.1/His C (Invitrogen) 
containing the FLAG epitope and into 
a version of the eukaryotic expres-
sion vector pcDNA3.1/HisMyc A 
(Invitrogen) containing the His epit-
ope, respectively. The constructs were 
verified by DNA sequencing.
The plasmids encoding HA-rpL3, 
HA-NPM, rpL7a-His and GST-rpL3 
were available.24 The plasmids pWWP, 
pWP124, pWP101 and pWPdel-SmaI 
were kindly provided by Dr. Yoshihiro 
Sowa.29
The recombinant proteins GST-
rpL3 and GST were produced as pre-
viously reported.24
RNA interference. The siRNAs 
targeting NPM were purchased from 
Santa Cruz Biotechnology (Santa 
Cruz Biotechnology).
To stably silence p21, Calu-6 cells 
were seeded the day before transfec-
tion in a 60-mm plate, and 24 h later 
they were transfected with 2 μg of a 
p21 short hairpin RNA (shRNA) 
expressing pSM2c vector contained in the Expression Arrest™ 
human shRNA library (Open Biosystems). Transfected cells 
were selected with 1 μg/ml of puromycin (Sigma-Aldrich) for 7 
d, and then the p21 depletion was evaluated by western blotting.
The sense strand of the p21 shRNA sequence is: 5'- TGC 
TGT TGA CAG TGA GCG ACC AGC CTC TGG CAT TAG 
AAT TTA GTG AAG CCA CAG ATG TAA ATT CTA ATG 
CCA GAG GCT GGG TGC CTA CTG CCT CGG A-3'.
A short hairpin non-silencing construct was used as control.
PCR. Reverse transcriptase-PCR analysis was performed as 
described previously.24 The primers used to amplify p21 cDNA 
and β-actin, were reported in Table 1.
Real-time PCR was used to analyze DNA in ChIP experi-
ments as described in this section (see sub-section “Chromatin 
immunoprecipitation”).
p21ΔCalu-6 cell line, derived from Calu-6 cell line and stably 
silenced for p21, was grown in DMEM supplemented with 10% 
fetal bovine serum (FBS), 0.1 mM non-essential amino acids 
(Euroclone), 2 mM L-glutamine, penicillin-streptomycin 50 U/
ml and 0.5 μg/ml puromycin (Sigma-Aldrich).
siRNA transfections were performed in Calu-6 cells (2.5 × 
106 cells, 6 mm-well plate) at a concentration of 150 nM using 
Oligofectamine Reagent (Invitrogen) according to the manufac-
turer’s instructions.
Plasmids were transfected in Calu-6 cells and p21ΔCalu-6 
cells (2.5 × 106 cells, 60 mm-well plate) by using Lipofectamine 
2000 (Invitrogen) according to the manufacturer’s instruction.
After DNA transfections, RNA and proteins were extracted 
by using the Trizol procedure (Invitrogen) for RT-PCR analysis 
and western blot, respectively.
Figure 9. Role of p21 on rpL3-mediated cell cycle arrest and apoptosis. (A) Protein extracts from 
Calu-6 cells and p21ΔCalu-6 cells transiently transfected with 1 μg of pHA-rpL3 were analyzed by WB 
assay with antibodies directed against the HA tag and p21. Loading in the gel lanes was controlled 
by detection of α-tubulin protein. The same samples were analyzed for DNA content by propidium 
iodide staining, and $uorescence was measured by $ow cytometry 24 h after transfection. (B) Protein 
extracts from Calu-6 cells and p21ΔCalu-6 transiently transfected with 2 μg of pHA-rpL3 were ana-
lyzed by WB assay with antibodies directed against the HA tag and p21. Loading in the gel lanes was 
controlled by detection of α-tubulin protein. The same samples were analyzed for DNA content by 
propidium iodide staining, and $uorescence was measured by $ow cytometry 24 h after transfection.
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Western blotting. Western blotting assay was performed as 
described previously,24 using antibodies anti-rpL3 (Primm), anti-
FLAG (Sigma-Aldrich), anti-Sp1 (Millipore), anti-p21, anti-
NPM, anti-HA, anti-His, anti-PARP and anti-α-tubulin (Santa 
Cruz Biotechnology).
Chromatin immunoprecipitation. Chromatin immunopre-
cipitation (ChIP) assay was performed as previously reported,27 
using anti-rpL3, anti-NPM, anti-Sp1 antibodies or normal 
mouse IgG. Aliquots of DNA-proteins immunocomplexes were 
resolved by 12% SDS-gel electrophoresis and transferred into 
nitrocellulose filters analyzed by western blotting. The chroma-
tin was extracted from the remaining aliquots of DNA-proteins 
immunocomplexes, the protein-DNA crosslink was reversed, 
and the proteins were digested with proteinase K. DNA was then 
purified and analyzed by real-time PCR analysis with the prim-
ers reported in Table 1 (p21 promoter -194/+88 and p21 3'-UTR 
+3455/+3771), using SYBR GreenEr qPCR SuperMix Universal 
(Invitrogen) following the manufacturer’s instructions.
Dual luciferase assay. Luciferase assays were performed 
with the Dual-Glo Luciferase assay system (Promega) following 
manufacturer’s instructions. Samples were read with Turner 
Luminometer and expressed as relative luciferase, i.e., RT/RC, 
where RT and RC are (Firefly luciferase)/(Renilla luciferase).
Flow cytometry. Cell cycle analysis, BrdU (5'-Bromo-
2'-deoxyuridine) incorporation and tetramethylrhodamine 
ethyl ester (TMRE) staining were performed as previously 
reported.46,47 Samples were analyzed by a CyAn ADP Flow 
Cytometer (DAKOCytomation) and quantified using Summit 
Software.
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